Public Disclosures

These tables provide details of approved research proposals that have published or presented their results.

2024

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetrics Score
4922, 3274Diane van der Woude Leiden University Medical Center​ Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisTakase-Minegishi, K., Böhringer, S., Nam, J.L., Kaneko, Y., Behrens, F., Saevarsdottir, S., Detert, J., Leirisalo-Repo, M., van der Heijde, D., Landewé, R. and Ramiro, S., 2024. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology, p.keae113.

DoI: 10.1093/rheumatology/keae113
AbbVie, Pfizer0
5435Matthew Gilbert University of Vermont Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled TrialGilbert, M.P., Skelly, J., Hernandez, A.F., Green, J.B., Krychtiuk, K.A., Granger, C.B., Leiter, L.A., McMurray, J.J., Del Prato, S. and Pratley, R.E., 2024. Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism.

Doi: 10.1111/dom.15479
GlaxoSmithKline18
5456Ramona Belfiore-Oshan Critical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy J. Wilk, V. Aggarwal, M. Pauley, D. Corey, D. Conrado, K. Lingineni, J. Morales, D. Yoon, J. Burton, J. Larkindale, S. Ma, C. Hovinga, T. Martinez, K. Romero, R. Belfiore-Oshan, S. Kim. A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES.

American Society for Clinical Pharmacology & Therapeutics. [See Browse by Poster Title tab]. Poster PII-179. 2024.
CureDuchenneN/A
5483David McAllister University of Glasgow Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.Lees, J., Crowther, J., Hanlon, P., Butterly, E.W., Wild, S.H., Mair, F., Guthrie, B., Gillies, K., Dias, S., Welton, N.J. and Katikireddi, S.V., 2024. Participant characteristics and exclusion from phase 3/4 industry funded trials of chronic medical conditions: meta-analysis of individual participant level data. BMJ medicine, 3(1).

Doi: 10.1136/bmjmed-2023-000732
Boehringer Ingelheim, Lilly, Roche, Takeda, UCB1
5985, 5327Jose Antonio Pereira da Silva Universidade de Coimbra, Portugal Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysisDuarte, C., Ferreira, R.J., Welsing, P.M., Jacobs, J.W., Gossec, L., Machado, P.M., van der Heijde, D. and da Silva, J.A.P., 2024. Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?. RMD open, 10(1), p.e003972.

Doi: 10.1136/rmdopen-2023-003972
AbbVie, Pfizer, Roche, UCB2
6495, 5485Günter Höglinger Hanover Medical School Application of improved statistical methodologies for clinical trials in Progressive Supranuclear PalsyKrotka, P., Posch, M., Gewily, M., Höglinger, G. and Roig, M.B., 2024. Statistical modeling to adjust for time trends in adaptive platform trials utilizing non-concurrent controls. arXiv preprint arXiv:2403.14348.

Doi: 10.48550/arXiv.2403.14348
AbbVie0
6551Siddharth Singh University of California San Diego Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID RegistryAhuja, D., Luo, J., Qi, Y., Syal, G., Boland, B.S., Chang, J., Ma, C., Jairath, V., Xu, R. and Singh, S., 2024. Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn’s Disease: Secondary Analysis of the PYRAMID Registry. Clinical Gastroenterology and Hepatology.

Doi: 10.1016/j.cgh.2024.01.003
AbbVie1
6551Siddharth Singh University of California San Diego Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID RegistryAhuja, D., Luo, J., Qi, Y., Syal, G., Boland, B., Chang, J., Ma, C., Jairath, V., Xu, R. and Singh, S., 2024. IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN’S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY. Inflammatory Bowel Diseases, S1(30), p.S1.

Doi: 10.1093/ibd/izae020.001
AbbVie1
6758Qian Chen Hubei Cancer Hospital Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapyChen, Q., Yuan, S., Liu, N., Wang, H., Shang, X., Ma, X., Sun, Y., Wei, C., Liu, L., Wang, X. and Liu, Y. Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis. JCO 42, 20570. (2024).

Doi:10.1200/JCO.2024.42.16_suppl.e20570
RocheN/A
6759, 5936Zhi Xiao Xiangya Hospital, Central-South University Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapyDing, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Wang, G., Tang, J., Cao, J. and He, L., 2024. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial. Breast Cancer Research, 26(1), pp.1-10.

Doi: 10.1186/s13058-023-01761-x
Roche12
6762, 5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical University Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Zhou, J.G., Yang, J., Wang, H., Wong, A.H.H., Tan, F., Chen, X., Shen, G., Wang, Y.J., Frey, B., Fietkau, R. and Hecht, M., Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy.

Doi: 10.1136/bmjonc-2023-000128
Bristol Myers Squibb, Project Data Sphere, Roche7
6860Nicholas Lange Columbia UniversityBelatacept in obese kidney transplant recipientsLange, N.W., King, K., Husain, S.A., Salerno, D.M., Tsapepas, D.S., Hedvat, J., Yu, M. and Mohan, S., 2024. Obesity is associated with a higher incidence of rejection in patients on belatacept: a pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials. American Journal of Transplantation.

Doi: 10.1016/j.ajt.2024.02.015
Bristol Myers Squibb4
6866Andy Lim Monash University Meta-analysis of early stroke recurrence rate in minor strokeLim, A., Ma, H., Johnston, S.C., Singhal, S., Muthusamy, S., Wang, Y., Pan, Y., Coutts, S.B., Hill, M.D., Ois, A. and Kapral, M.K., 2023. Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies. Journal of the American Heart Association, p.e032471.

Doi: 10.1161/JAHA.123.032471
AstraZeneca3
7074Gregory YH Lip University of Liverpool Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesCorica, B., Romiti, G.F., Proietti, M., Mei, D.A., Boriani, G., Ding, W.Y., Olshansky, B., Huisman, M.V. and Lip, G.Y.H., 2024. Early rhythm control in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III. Europace, 26(Supplement_1), pp.euae102-066.

Doi: 10.1093/europace/euae102.066
Boehringer Ingelheim0
7074Gregory YH Lip University of Liverpool Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesLam, S.H.M., Romiti, G.F., Olshansky, B., Chao, T.F., Huisman, M.V. and Lip, G.Y.H., 2024. Combination therapy of beta-blockers and digoxin is associated with increased risk of major adverse cardiovascular events and all-cause mortality in patients with atrial fibrillation: a report from the GLORIA–AF registry. Internal and Emergency Medicine, pp.1-10.

Doi: 10.1007/s11739-024-03629-0
Boehringer Ingelheim3
7127Alexa Kimball Beth Israel Deaconess Medical Center Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis SuppurativaGunter, S.J., Holcomb, Z.E., Lam, B.D., Porter, M.L. and Kimball, A.B., 2024. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab. JAMA dermatology.

Doi: 10.1001/jamadermatol.2024.1075
AbbVie2
7142Sara Tedeschi Brigham and Women’s Hospital Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with goutTedeschi, S.K., Hayashi, K., Zhang, Y., Choi, H. and Solomon, D.H., 2024. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. Annals of the Rheumatic Diseases.

Doi: 10.1136/ard-2024-225761
Takeda4
7156Angelina Tjokrowidjaja University of Sydney Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysisTjokrowidjaja, A., Friedlander, M.L., Ledermann, J.A., Coleman, R.L., Mirza, M.R., Matulonis, U.A., Pujade-Lauraine, E., Lord, S.J., Scott, C.L., Goble, S. and York, W., 2024. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly (ADP-ribose) Polymerase Inhibitor. Journal of Clinical Oncology, JCO-23.

Doi: 10.1200/JCO.23.01182
AstraZeneca28
7322Zhengfei Zhu Fudan University Shanghai Cancer Center Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasisGuo, T., Zhou, Y., Liang, F., Wang, Z., Bourbonne, V., Käsmann, L., Sundahl, N., Wu, A.J.C., Ni, J. and Zhu, Z., 2024. Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials. Translational Lung Cancer Research, 13(1), p.126.

Doi: 10.21037/tlcr-23-792
Roche1
7322Zhengfei Zhu Fudan University Shanghai Cancer Center Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasisZhou, Y., Guo, T., Liang, F., Wang, Z., Zhang, J., Ni, J. and Zhu, Z., 2024. Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150. Cancer.

Doi: 10.1002/cncr.35242
Roche4
7493Nina Hilkens Radboudumc Nijmegen Blood pressure variability and progression of white matter hyperintensities after ischemic strokesHilkens, N.A., de Leeuw, F.E., Klijn, C.J. and Richard, E., 2024. Blood pressure variability and white matter hyperintensities after ischemic stroke. Cerebral Circulation-Cognition and Behavior, p.100205.

Doi: 10.1016/j.cccb.2024.100205
Boehringer Ingelheim1
7549Vipul Jairath Alimentiv Inc Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative ColitisSolitano, V., Panaccione, R., Sands, B.E., Wang, Z., Zou, G., Peyrin-Biroulet, L., Danese, S., Cornfield, L.J., Feagan, B.G., Singh, S. and Jairath, V., 2024. P280 Comparative responsiveness of disease activity indices in moderately-to-severely active Ulcerative Colitis: a post-hoc analysis of the UNIFI trial. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i647-i648.

Doi: 1093/ecco-jcc/jjad212.0410
AbbVie, Johnson & Johnson, Takeda1
7587Yashmin Karten Critical Path Institute Development of model-informed drug development tools for Alzheimer's DiseaseSivakumaran S., Karten Y., Cullen N., Lau C., Priest E., White H., Irizarry M. DE-RISKING CLINICAL TRIAL DESIGN VIA MODEL-INFORMED DRUG DEVELOPMENT WITH THE CRITICAL PATH FOR ALZHEIMER’S DISEASE CONSORTIUM.

Alzheimer's & Parkinson's Diseases Conference. Abstract Shift 2-0149. 2024.
LillyN/A
7595Ashley HopkinsFlinders University Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatmentParent N, Hopkins AM, Sorich MJ. Machine learning for enhanced survival prediction from tumour growth inhibition data.

Population Approach Group of Australia and New Zealand (PAGANZ). Oral Presentation. 2024.
RocheN/A
7595Ashley HopkinsFlinders University Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatmentLi LX, Hopkins AM, Sorich MJ. Methodologically appropriate evaluation of continuous BMI as a clinical predictor of chemoimmunotherapy efficacy in advanced non-small cell lung cancer.

Population Approach Group of Australia and New Zealand (PAGANZ). Oral Presentation. 2024.
RocheN/A
7598Harry Southworth Data Clarity Consulting Ltd Exploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data miningSouthworth H., Schubiner H. Statistical investigation of comorbidities of back pain in the medical history data from clinical trials of healthy subjects. 2024. Open Science Framework (OSF).

Doi: 10.17605/OSF.IO/APXUT
AstraZeneca, GlaxoSmithKline0
7601Guru Sonpavde AdventHealth Cancer Institute Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitorsGraser, C., McDonald, T.O., Sonpavde, G. and Michor, F., 2024. Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab. Cancer Research, 84(6_Supplement), pp.2392-2392.

Doi: 10.1158/1538-7445.AM2024-2392
Roche0
7606Amber Salter University of Texas Southwestern Medical Center Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple SclerosisSalter, A., Lancia, S., Fitzgerald, K., Ann Marrie, R., 2024. Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations. Neurology. 102(5).

doi: 10.1212/WNL.0000000000209135
Roche5
7656Neeraj Narula Hamilton Health Sciences Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative ColitisNarula, N., Hamam, H., Wong, E.C., Marshall, J.K., Jairath, V., Hanauer, S.B., Reinisch, W. and Dulai, P.S., 2024. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i1308-i1308.

Doi: 10.1093/ecco-jcc/jjad212.0819
AbbVie, Johnson & Johnson, Pfizer, Takeda1
7662Benoit YouUniversité Claude Bernard LyonPrognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA)A. Carrot, A., Oudard, S., Fizazi, K., Maillet, D., Sartor, O., Freyer, G., You, B. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO Clin Cancer Inform 8, e2300208(2024).

DOI :10.1200/CCI.23.00208
Sanofi1
7743Caroline Quach CHU Sainte-Justine Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-AnalysisTadount, F., Kiely, M., Assi, A., Rafferty, E., Sadarangani, M., MacDonald, S.E. and Quach, C., 2024, April. Sex Differences in the Immunogenicity and Efficacy of Seasonal Influenza Vaccines: A Meta-analysis of Randomized-Controlled Trials. In Open Forum Infectious Diseases (p. ofae222). Oxford University Press.

Doi: 10.1093/ofid/ofae222
Sanofi0
7779Luís Inês University of Beira Interior Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus.Jesus, D., Matos, A., Henriques, C., Doria, A. and Inês, L.S., 2024. P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials.

Doi: 10.1136/lupus-2024-el.181
AstraZeneca1
7779Luís Inês University of Beira Interior Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus.Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L.S., 2024. P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials.

Doi: 10.1136/lupus-2024-el.121
AstraZeneca1
7779Luís Inês University of Beira Interior Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus.Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L.S., 2024. O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials.

Doi: 10.1136/lupus-2024-el.31
AstraZeneca0
7848Jennifer Lund University of North Carolina at Chapel Hill Improving Colon Cancer Therapy Decisions by Extending Trial RepresentationLund, J.L., Webster-Clark, M.A., Westreich, D., Sanoff, H.K., Robert, N., Frytak, J.R., Boyd, M., Shmuel, S., Stürmer, T. and Keil, A.P., 2024. Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice. Epidemiology, 35(2), pp.241-251.

Doi: 10.1097/EDE.0000000000001694
Sanofi1
7854Vipul Jairath University of Western Ontario Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trialsVuyyuru, S.K., Ma, C., Nguyen, T.M., Zou, G., Peyrin-Biroulet, L., Danese, S., Dulai, P., Narula, N., Singh, S. and Jairath, V., 2024. Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials. eClinicalMedicine, 72.

Doi: 10.1016/j.eclinm.2024.102621
AbbVie, Johnson & Johnson, Pfizer, Takeda14
7856Evandro de Azambuja Institut Jules Bordet Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survivalDebien, V., Agostinetto, E., Bruzzone, M., Ceppi, M., Martins-Branco, D., Molinelli, C., Jacobs, F., Nader-Marta, G., Lambertini, M. and de Azambuja, E., 2024. The impact of initial tumor response on survival outcomes of patients with HER2-positive advanced breast cancer treated with docetaxel, trastuzumab, and pertuzumab: an exploratory analysis of the CLEOPATRA trial. Clinical Breast Cancer.

Doi: 10.1016/j.clbc.2024.02.012
Roche16
8052Wataru Fukuokaya The Jikei University School of Medicine Association of serum magnesium levels with effectiveness of atezolizumab in advanced urothelial carcinomaFukuokaya, W., Akazawa, K. and Kimura, T., 2024. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma. Anticancer Research, 44(5), pp.2117-2123.

Doi: 10.21873/anticanres.17017
Roche1
8440David SeiffgeInsel Gruppe AGAndexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC Siepen, B.M., Polymeris, A., Shoamanesh, A., Connolly, S., Steiner, T., Poli, S., Lemmens, R., Goeldlin, M.B., Müller, M., Branca, M. and Rauch, J., 2023. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors—Individual patient data analysis of ANNEXA-4 and TICH-NOAC. International Journal of Stroke, p.17474930 241230209.

Doi: 10.1177/17474930241230209
AstraZeneca18
8561Dale MorrisonThe University of MelbourneIMPROVING EXERCISE WITH TYPE 1 DIABETESMorrison, D., Vogrin, S. and Zaharieva, D.P., 2024. Assessment of Glycemia Risk Index and Standard Continuous Glucose Monitoring Metrics in a Real-World Setting of Exercise in Adults With Type 1 Diabetes: A Post-Hoc Analysis of the Type 1 Diabetes and Exercise Initiative.

Doi: 10.1177/19322968241246458
Jaeb Center for Health Research Foundation, Inc.0
8686Andrea E. van der Meulen - de Jong Leiden University Medical Center Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitisLoveikyte, R., Voorneveld, P.W., Dijkstra, G. and van der Meulen-de Jong, A.E., 2024. P923 Haematological abnormalities during treatment with Janus kinase inhibitors in patients with Ulcerative Colitis: a post hoc analysis. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i1681-i1681.

Doi: 10.1093/ecco-jcc/jjad212.1053
Pfizer1
8699Niklas Klümper University Hospital BonnEvaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancersKlümper, N., Cox, A., Eckstein, M., Kuppe, C., Ritter, M., Brossart, P., Luetkens, J., Hölzel, M., Stein, J. and Saal, J., 2024. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. European Journal of Cancer, p.114089.

Doi: 10.1016/j.ejca.2024.114089
Roche8
8837Erin TallonChildren's Mercy Kansas CityDevelopment of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 DiabetesPanfil K, Tallon EM, Lockee B, Williams DD, Patton SR, Clements M. Impact of moderate-to-vigorous physical activity on continuous glucose monitor-derived metrics in youth with type 1 diabetes. Diabetes Technol Ther 2024; 26(S2):EV257.

Doi: 10.1089/dia.2024.2525.abstracts
Jaeb Center for Health Research Foundation, Inc.8
8926Alessio CortelliniImperial College London The putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials.Cortellini A., Santo V., Brunetti L., Mangani D., Anderson A.C., Vincenzi B., Tonini G., Takada K., Naqash A.R., Ricciuti B., Pinato D.J. Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials. JCO 42, 2607-2607(2024).

Doi: 10.1200/JCO.2024.42.16_suppl.2607
Roche0
8933João Pedro Ferreira University of Porto Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozinFerreira, J.P., Zannad, F., Packer, M., Filippatos, G., Pocock, S.J., Vasques‐Nóvoa, F., Böhm, M., Butler, J. and Anker, S., 2024. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis. European Journal of Heart Failure.

Doi: 10.1002/ejhf.3180
Boehringer Ingelheim1
8957Dean Bodenham Imperial College London Two-sample testing for clinical trials data with missing valuesZeng Y., Adams N.M., Bodenham D.A. 2024. On two-sample testing for data with arbitrarily missing values. arXiv preprint.

Doi: 10.48550/arXiv.2403.15327
Bayer1

2023

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetrics ScorePubMed Citation Total
3876Changyu Shen Beth Israel Deaconess Medical Center Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation Aggarwal R, Ruff C T, Virdone S, Perreault S, Kakkar A K, Palazzolo M G, Dorais M, Kayani G, Singer D E, Secemsky E, Piccini J, Tahir U A, Shen C, 7 Yeh R W. (2023). Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation.

Doi: 10.1161/CIRCULATIONAHA.123.064556
Boehringer Ingelheim, Daiichi Sankyo1282
4113Lesley InkerTufts Medical CenterChronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT)Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):183-192.

doi : 10.2215/CJN.0000000000000050
GlaxoSmithKline, Takeda121
4113Lesley Inker Tufts Medical Center Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT)Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J. and Goicoechea, M., 2023. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, pp.1-10.

Doi: 10.1038/s41591-023-02418-0
GlaxoSmithKline, Takeda596
4115Amir MahabadiUniversity Hospital Essen, West German Heart and Vascular Center Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trialsVogel LH, Dykun I, Raggi P, Schmermund A, Rassaf T, Mahabadi AA. High- vs. Low-Intensity Statin Therapy and Changes in Coronary Artery Calcification Density after One Year. Journal of Clinical Medicine. 2023; 12(2):476.

doi: https://doi.org/10.3390/jcm12020476
Pfizer31
4120Merryn Voysey University of Oxford The immunogenicity and sero-efficacy of pneumococcal vaccinesFeng, S., McLellan, J., Pidduck, N., Roberts, N., Higgins, J.P., Choi, Y., Izu, A., Jit, M., Madhi, S.A., Mulholland, K. and Pollard, A.J., 2023. Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data. EClinicalMedicine, 61.

doi: 10.1016/j.eclinm.2023.102073
Pfizer20
4922, 3274Diane van der WoudeLeiden University Medical CenterEffect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisTakase-Minegishi K, Böhringer S, Nam J, et al. POS0181 THE IMPACT OF AUTOANTIBODIES (RF AND ACPA) ON THE EFFICACY OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.

Annals of the Rheumatic Diseases 2023;82:315-31 6.
AbbVie, Pfizer0N/A
4949, 3190Vivek RudrapatnaUniversity of California San Francisco Efficacy of Crohn’s Disease Treatment Stratified by Disease PhenotypeRudrapatna, V., Ravindranath, V., Arneson, D., Mosenia, A., Butte, A. and Wang, S., 2023. S936 Optimizing Treatment Selection in Crohn’s Disease Using Patient-Specific Features: An Individual Participant Data Meta-Analysis of Fifteen Randomized Controlled Trials. Official journal of the American College of Gastroenterology| ACG, 118(10S), pp.S701-S702.

Doi: 10.14309/01.ajg.0000953384.20574.a3
AbbVie, Biogen, Johnson & Johnson, Takeda, UCB01
4949, 3190Vivek RudrapatnaUniversity of California San Francisco Efficacy of Crohn’s Disease Treatment Stratified by Disease PhenotypeRudrapatna, V.A., Ravindranath, V.G., Arneson, D.V., Mosenia, A., Butte, A.J. and Wang, S., 2023. Sequential regression and simulation: a method for estimating causal effects from heterogeneous clinical trials without a common control group. BMC Medical Research Methodology, 23(1), pp.1-12.

Doi: 10.1186/s12874-023-02020-5
AbbVie, Biogen, Johnson & Johnson, Takeda, UCB00
4949, 3190Vivek Rudrapatna University of California San Francisco Efficacy of Crohn’s Disease Treatment Stratified by Disease PhenotypeRudrapatna, V.A., Ravindranath, V., Arneson, D.V., Mosenia, A., Butte, A.J. and Wang, S., 2023. Personalizing treatment selection in Crohn's disease: a meta-analysis of individual participant data from fifteen randomized controlled trials. medRxiv, pp.2023-11.

Doi: 10.1101/2023.11.10.23291837
AbbVie, Biogen, Johnson & Johnson, Takeda, UCB0N/A
5080Joel SkaistisBeaumont Health Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker LevelJ. Skaistis, J. George, H.C. Diener. Dabigatran Treatment in Embolic Stroke
of Undetermined Source and Elevated Biomarkers: the RE-SPECT ESUS Trial. CJC Open (2023).

doi : 10.1016/j.cjco.2022.12.013
Boehringer Ingelheim0N/A
5209Bruce Perkins University of Toronto TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOLSong, C., Dhaliwal, S., Bapat, P., Scarr, D., Bakhsh, A., Budram, D., Verhoeff, N.J., Weisman, A., Fralick, M., Ivers, N.M. and Cherney, D.Z., 2023. Point-of-care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care.

Doi: 10.2337/dc23-0840
Boehringer Ingelheim00
5276Yan LuoKyoto UniversityPredicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis Luo, Y., Chalkou, K., Funada, S., Salanti, G. and Furukawa, T.A., 2023. Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis. JAMA Network Open, 6(6), pp.e2321398-e2321398.

doi:10.1001/jamanetworkopen.2023.21398
UCB160
5294Daniel CaldeiraUniversity of Lisbon/CCUL The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY Caldeira, D., Alves da Silva, P. and Pinto, F.J., 2023. Clinical outcomes of anticoagulated patients with atrial fibrillation after falls or head injury: insights from RE-LY. Stroke. 2023;54:1656–1659.

doi : 10.1161/STROKEAHA.122.041628
Boehringer Ingelheim31
5456Ramona Belfiore-Oshan Critical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy Belfiore-Oshan, R., Aggarwal, V., Wilk, J., Pauley, M., Corey, D., Romero, K., Hovinga, C., Martinez, T., Lingineni, K., Yoon, D., Kim, S. and Morales, J., 2023. P146 A clinical trial simulation tool to accelerate trial design in DMD: description of the traphical user interface features and applications. Neuromuscular Disorders, 33, p.S84.

Doi: 10.1016/j.nmd.2023.07.081
CureDuchenne0N/A
5483David McAllisterUniversity of GlasgowAssessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.Jennifer Lees. The impact of age, sex, comorbidity count and race/ethnicity on attrition and screen failure from trials. Kidney Health Symposium 2023, Event held on 24th Feb 2023. (From 34-58 mins)

https://ctc.usyd.edu.au/news-events/kidney-health-symposium-2023/
Boehringer Ingelheim, Lilly, Roche, Takeda, UCBN/AN/A
5483David McAllister University of Glasgow Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.Lees, J.S., Crowther, J., Hanlon, P., Butterly, E., Wild, S., Mair, F.S., Guthrie, B., Gillies, K., Dias, S., Welton, N.J. and Katikireddi, S.V., 2023. Participant characteristics and exclusion from trials: a meta-analysis of individual participant-level data from phase 3/4 industry-funded trials in chronic medical conditions. medRxiv, pp.2023-04.

Doi: 10.1101/2023.04.14.23288549
Boehringer Ingelheim, Lilly, Roche, Takeda, UCB0N/A
5852Marliese AlexanderPeter MacCallum Cancer Centre Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysisAlexander M, Jachno K, Phillips KA, Seymour JF, Slavin MA, Cheung A, Shen V, Maarouf D, Wolfe R, Lingaratnam S. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice. 2023 Jun 16.

doi : 10.1177/10781552231180875
Roche00
5924Iris SommerUniversity Medical Center GroningenMeta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodiesd’Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. Published online June 26, 2023.

doi:10.1001/jamaneurol.2023.1835
AbbVie, GlaxoSmithKline, Johnson & Johnson830
5925Min Hwan KimYonsei University College of MedicineAnalysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical responseKim, C.G., Kim, M.H., Kim, J.H. et al. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates. Breast Cancer Res 25, 4 (2023).

doi : 10.1186/s13058-022-01601-4
Pfizer0N/A
5950Shirley Wang Brigham and Women's Hospital Understanding effectiveness of new drugs in older adults shortly after market entryShin, H., Wang, S.V., Kim, D.H., Alt, E., Mahesri, M., Bessette, L.G., Schneeweiss, S. and Najafzadeh, M. Predicting treatment effects of a new‐to‐market drug in clinical practice based on phase III randomized trial results. Clinical Pharmacology & Therapeutics.

Doi: 10.1002/cpt.2983
Boehringer Ingelheim10
5950Shirley Wang Brigham and Women's Hospital Understanding effectiveness of new drugs in older adults shortly after market entryShin, H., Wang, S., Kim, D.H., Alt, E., Mahesri, M., Bessette, L.G., Schneeweiss, S. and NajafZadeh, M., 2023. MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results. Value in Health, 26(6), p.S285.

Doi: 10.1016/j.jval.2023.03.1576
Boehringer Ingelheim0N/A
5951, 4543Mathilde NijkeuterUMC UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolismMaria A de Winter, Harry R Büller, Marc Carrier, Alexander T Cohen, John-Bjarne Hansen, Karin A H Kaasjager, Ajay K Kakkar, Saskia Middeldorp, Gary E Raskob, Henrik T Sørensen, Frank L J Visseren, Philip S Wells, Jannick A N Dorresteijn, Mathilde Nijkeuter, VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. European Heart Journal, 2023;. ehac776.

doi: 10.1093/eurheartj/ehac776
Boehringer Ingelheim, Daiichi Sankyo1466
5985, 5327Jose Antonio Pereira da Silva Universidade de Coimbra, Portugal Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysisDuarte, C., Ferreira, R.J.O., Welsing, P., Jacobs, J.W.G., Gossec, L., Machado, P., Van der Heijde, D. and Da Silva, J.A.P., 2023. OP0189 REMISSION CRITERIA GUIDING IMMUNOSUPPRESSIVE THERAPY IN RA: WHICH IS BEST FITTED FOR THIS PURPOSE?.

Doi: 10.1136/annrheumdis-2023-eular.1853
AbbVie, Pfizer, Roche, UCB0N/A
6008David HsiehUniversity of Texas Southwestern Medical CenterPatterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors.Espinoza, M., Muiquith, M., Lim, M., Zhu, H., Singal, A. G., & Hsiehchen, D. (2023). Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: Post-hoc analysis of IMbrave150. Gastroenterology.

doi : 10.1053/j.gastro.2023.02.042
RocheN/A10
6008David Hsieh University of Texas Southwestern Medical CenterPatterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors.Lim, M., Muquith, M., Miramontes, B., Lee, C.J., Espinoza, M., Huang, Y.H. and Hsiehchen, D., 2023. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. Hepatology, pp.10-1097.

Doi: 10.1097/HEP.0000000000000494
Roche33
6063Wiesje van der Flier Amsterdam UMC, VUmc Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s diseaseDubbelman, M.A., Vromen, E.M., Tijms, B.M., Ottenhoff, L., Vijverberg, E.G., Prins, N.D., van der Flier, W.M. and Sikkes, S.A., 2023, July. P1-743 - Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach.

In Alzheimer's Association International Conference. ALZ.
Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, LillyN/AN/A
6104Pratik Sinha Washington University Heterogeneous treatment effects in molecular phenotypes of sepsisSinha, P., Kerchberger, V.E., Willmore, A., Chambers, J., Zhuo, H., Abbott, J., Jones, C., Wickersham, N., Wu, N., Neyton, L. and Langelier, C.R., 2023. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. The Lancet Respiratory Medicine.

Doi:10.1016/S2213-2600(23)00237-0
Lilly2810
6475Tobias PolakErasmus Medical CenterCombining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenibPolak, T.B., Labrecque, J.A., Groot, C.A. and van Rosmalen, J., 2023. Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access. arXiv preprint.

doi: arXiv:2306.01557.
Roche0N/A
6495, 5485Günter Höglinger Hanover Medical School Application of improved statistical methodologies for clinical trials in Progressive Supranuclear PalsyYousefi, E., Gewily, M., König, F., Höglinger, G., Hopfner, F., Karlsson, M.O., Ristl, R., Zehetmayer, S. and Posch, M., 2023. Efficiency of Multivariate Tests in Trials in Progressive Supranuclear Palsy. arXiv preprint arXiv:2312.08169.

Doi: 10.48550/arXiv.2312.08169
AbbVie0N/A
6499, 5323, 5289Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancerModi, N., Abuhelwa, A.Y., Rowland, A., Menz, B.D., McKinnon, R.A., Sorich, M.J. and Hopkins, A.M., 2023. Association between patient-reported outcomes and therapeutic outcomes in patients with breast cancer: A pooled individual-participant data analysis.

Doi: 10.1200/JCO.2023.41.16_suppl.530
Lilly, Roche, Pfizer0N/A
6521Ethan AltUniversity of North Carolina at Chapel HillBayesian probability of success for multivariate generalized linear modelsAlt, E. M., Psioda, M. A., & Ibrahim, J. G. (2023). A Bayesian approach to study design and analysis with type I error rate control for response variables of mixed types. Statistics in Medicine.

doi: 10.1002/sim.9696
Biogen40
6544Angela WuUniversity of OxfordInvestigating the association between smoking cessation and mental health in people with and without psychiatric disordersWu, A.D., Gao, M., Aveyard, P. and Taylor, G., 2023. Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders. JAMA Network Open, 6(5), pp.e2316111-e2316111.

Doi: 10.1001/jamanetworkopen.2023.16111
Pfizer4422
6550James BrorsonThe University of ChicagoExamination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrenceJames R Brorson, Shyam Prabhakaran, S Claiborne Johnston, Mihai Giurcanu. Abstract WMP61: Vulnerable And Stabilized States After Cerebral Ischemic Events: Implications Of Kinetic Modeling In The POINT, SOCRATES, And THALES Trials. Stroke. 2023;54:AWMP61.

doi: 10.1161/str.54.suppl_1.WMP61
AstraZeneca1N/A
6550James Brorson The University of Chicago Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrenceBrorson, J.R., Giurcanu, M., Prabhakaran, S. and Johnston, S.C., 2023. Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology.

Doi: 10.1212/WNL.0000000000207904
AstraZeneca00
6594Manju SubramanianBoston Medical CenterThe Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled AnalysisNayan Sanjiv, Pawarissara Osathanugrah, Steven Ness, Xuejing Chen, Nicole Siegel, Manju L Subramanian. Impact of Race on Treatment of Ranibizumab in Diabetic Macular Edema: A Pooled Analysis. Invest. Ophthalmol. Vis. Sci.

2023;64(8):2713.
RocheN/AN/A
6642Neeraj NarulaHamilton Health SciencesModified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohns DiseaseC Galts, N Narula, E Wong, W Reinisch. A116 OPTIMIZING CROHN’S DISEASE ENDOSCOPIC SCORING OPERATING CHARACTERISTICS TO ASSIST WITH THE ADVENT OF ARTIFICIAL INTELLIGENCE. Journal of the Canadian Association of Gastroenterology, Volume 6, Issue Supplement_1, March 2023, Page 63.

doi: 10.1093/jcag/gwac036.116
AbbVie1N/A
6712Yeon-Mok OhAsan Medical CenterDevelopment and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD)Lee JH, Kim S, Oh YM. A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2023;18:113-127.

doi : 10.2147/COPD.S389502
GlaxoSmithKline81
6712Yeon-Mok OhAsan Medical CenterDevelopment and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD)Jang Ho Lee, Sehee Kim, Yeon-Mok Oh. Development of a scoring model for the prediction of the effects of discontinuation or addition of inhaled corticosteroid in chronic obstructive pulmonary disease patients. Volume 28, Issue S1 Supplement: 26th Congress of the Asian Pacific Society of Respirology Above and Beyond, 17–20 November 2022, Seoul, Korea, February 2023, P45-46 AO07-3.

doi: 10.1111/resp.14433#14433-sec-0269
GlaxoSmithKline10
6716Nigam ShahStanford UniversityApplying machine learning tools to personalize dabigatran treatment decisionsXu, Y., Bechler, K., Callahan, A., & Shah, N. (2023). Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation. Journal of Biomedical Informatics, 104420.

doi :10.1016/j.jbi.2023.104420
Boehringer Ingelheim00
6732Yung-Chuan HuangFu Jen Catholic University HospitalDecision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation PatientsHuang Yongquan (2023). Risk Evaluation for Ischemic Stroke Patients with Non-Valvular Arrythmia by Using Integrated Multistage Machine Learning Predictive Scheme. (PhD thesis. Fu Jen Catholic University). National Digital Libraries of Theses and Dissertations in Taiwan.

https://hdl.handle.net/11296/zy9jzs
Boehringer IngelheimN/AN/A
6732Yung-Chuan HuangFu Jen Catholic University HospitalDecision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation PatientsHuang Y-C, Cheng Y-C, Jhou M-J, Chen M, Lu C-J. Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran. International Journal of Environmental Research and Public Health. 2023; 20(3):2359.

doi: 10.3390/ijerph20032359
Boehringer Ingelheim10
6759, 5936Zhi XiaoXiangya Hospital, Central-South UniversityRoles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapyXiao, Z., Ding, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Wang, G., Tang, J. and Can, J., 2023. 9P Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. ESMO Open, 8(1).

Doi: 10.1016/j.esmoop.2023.101233
Roche0N/A
6764Camila Olarte ParraLondon School of Hygiene and Tropical MedicineHypothetical estimand in clinical trials: an application of causal inference and missing data methodsOlarte Parra, C., Daniel, R.M., Wright, D. and Bartlett, J.W., 2023. Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial. arXiv e-prints, pp.arXiv-2308.

Doi: 10.48550/arXiv.2308.13085
AstraZenecaN/AN/A
6836Alana RojewskiMedical University of South CarolinaSmoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical TrialRojewski AM, Palmer AM, Baker NL, Toll BA. Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial. Nicotine and Tobacco Research. 2023 Jul 20:ntad126.

doi: 10.1093/ntr/ntad126
Pfizer00
6836Alana Rojewski Medical University of South Carolina Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical TrialRojewski A, Palmer AM, Baker NL, Toll, BA. SMOKING CESSATION PHARMACOTHERAPY EFFICACY IN COMORBID MEDICAL POPULATIONS: SECONDARY ANALYSIS OF THE
EAGLES RANDOMIZED CLINICAL TRIAL.

The Society for Research on Nicotine & Tobacco. POS1-12. 2023.
PfizerN/AN/A
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesGiulio Francesco Romiti, Marco Proietti, Niccolò Bonini, Wern Yew Ding, Giuseppe Boriani, Menno V. Huisman, Gregory Y.H. Lip. Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry. eClinicalMedicine, Volume 55, 2023, 101757.

doi: 10.1016/j.eclinm.2022.101757
Boehringer Ingelheim815
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesCorica B, Romiti GF, Proietti M, Mei DA, Boriani G, Chao TF, Olshansky B, Huisman MV, Lip GY, GLORIA-AF Investigators. Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry. InMayo Clinic Proceedings 2023 Aug 25.

doi : 10.1016/j.mayocp.2023.07.013
Boehringer Ingelheim80
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesRomiti GF, Corica B, Proietti M, Mei DA, Frydenlund J, Bisson A, Boriani G, Olshansky B, Chan YH, Huisman MV, Chao TF. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. eClinicalMedicine. 2023 Aug 25.

doi : 10.1016/j.eclinm.2023.102039
Boehringer Ingelheim52
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesCorica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a Risk Factor for Atrial Fibrillation-Related Stroke. Thromb Haemost. 2023 Oct 23.

doi: 10.1055/s-0043-1776394
Boehringer Ingelheim110
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesRomiti GF, Proietti M, Corica B, Bonini N, Boriani G, Huisman MV, Lip GYH; GLORIA‐AF Investigators. Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF. J Am Heart Assoc. 2023 Oct 17;12(20):e030565.

doi : 10.1161/JAHA.123.030565
Boehringer Ingelheim172
7074Gregory YH Lip University of Liverpool Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesCorica, B., Romiti, G.F., Proietti, M., Mei, D.A., Boriani, G., Chao, T.F., Olshansky, B., Huisman, M.V. and Lip, G.Y.H., 2023. Adverse outcomes according to metabolic status in obese and overweight patients with atrial fibrillation: a report from the GLORIA-AF Phase II and III Registry. European Heart Journal, 44(Supplement_2), pp.ehad655-432.

Doi: 10.1093/eurheartj/ehad655.432
Boehringer Ingelheim0N/A
7074Gregory YH Lip University of Liverpool Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesRomiti, G.F., Corica, B., Proietti, M., Mei, D.A., Frydenlund, J., Bisson, A., Boriani, G., Olshansky, B., Chan, Y.H., Huisman, M.V. and Chao, T.F., 2023. Oral anticoagulant use and outcomes in Asian patients with atrial fibrillation in the GLORIA-AF Registry. European Heart Journal, 44(Supplement_2), pp.ehad655-433.

Doi: 10.1093/eurheartj/ehad655.433
Boehringer Ingelheim1N/A
7074Gregory YH Lip University of Liverpool Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesRomiti, G.F., Proietti, M., Corica, B., Mei, D.A., Frost, F., Bisson, A., Boriani, G., Olshansky, B., Chao, T.F., Huisman, M.V. and Lip, G.Y.H., 2023. Impact of chronic obstructive pulmonary disease on the natural history of atrial fibrillation: a report from the GLORIA-AF registry phase II & III. European Heart Journal, 44(Supplement_2), pp.ehad655-573.

Doi: 10.1093/eurheartj/ehad655.573
Boehringer Ingelheim2N/A
7078Alberto MartiniSan Raffaele UniversityRole of body mass index and Beta Blockers in metastatic urothelial carcinomaRobesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Necchi A, Martini A. PD09-11 THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMvigor210 AND IMvigor211. The Journal of Urology. 2023 Apr;209(Supplement 4):page e244.

doi: 10.1097/JU.0000000000003240.11
Roche8N/A
7078Alberto MartiniSan Raffaele UniversityRole of body mass index and Beta Blockers in metastatic urothelial carcinomaRobesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials. BJU international.

doi: 10.1111/bju.16121
Roche141
7127Alexa KimballBeth Israel Deaconess Medical Center Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis SuppurativaGunter S, Porter M, Gibson R, Kimball AB. 423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa. Journal of Investigative Dermatology. 2023 May 1;143(5):S73.

https://www.jidonline.org/article/S0022-202X(23)00604-8/pdf
AbbVieN/AN/A
7142Sara Tedeschi Brigham and Women’s Hospital Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with goutTedeschi S, Hayashi K, Zhang Y, Choi H, Solomon D. Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out [abstract]. Arthritis Rheumatol.

2023; 75 (suppl 9).
TakedaN/AN/A
7159James SignorovitchAnalysis GroupAssociations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD)McDonald CM, Marden JR, Shieh PB, et al. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. Journal of Comparative Effectiveness Research. 2023 Feb:e220190.

doi : 10.57264/cer-2022-0190.
CureDuchenneN/A1
7161Wesley Kerr University of California, Los Angeles Real time monitoring of individual response to antiseizure medication treatment during clinical trialsKerr W, Kok N, Reddy A, Stacey W, Stern J, Pennell P, French J. Time to event trial endpoints best measured efficacy when seizure counting started during maintenance excluding titration.American Epilepsy Society Annual Meeting. [See Abstracts tab].

Poster 1.285. 2023
GlaxoSmithKline, Johnson & Johnson, UCBN/AN/A
7161Wesley Kerr University of California, Los Angeles Real time monitoring of individual response to antiseizure medication treatment during clinical trialsKerr W, Kok N, Reddy A, Stacey W, Stern J, Pennell P, French J. Time to prerandomization seizure count demonstrated efficacy of levetiracetam, lacosamide, lamotrigine, and brivaracetam with less placebo exposure. American Epilepsy Society Annual Meeting. [See Abstracts tab].

Poster 1.287. 2023
GlaxoSmithKline, Johnson & Johnson, UCBN/AN/A
7163Laura Mezquita Hospital Clinic and the Translational Genomics Group at IDIBAPS Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancersM. Roulleaux Dugage, M. Tagliamento, T. Gorria, A. Rochand, L. Garcin, S. Oudard, C. Thibault, V.M. Albarran Artahona, J.C. Laguna Montes, I. Nalda Ariza, F.J. Muñoz i Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixido, B. Besse, L. Mezquita, E. Auclin. 1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases. Annals of Oncology (2023) 34 (suppl_2): S755-S851.

doi : 10.1016/annonc/annonc1331
Project Data Sphere, RocheN/AN/A
7163Laura Mezquita Hospital Clinic and the Translational Genomics Group at IDIBAPS Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancersM. Roulleaux Dugage, T. Gorria, A. Rochand, L-M. Garcin, S. Oudard, V. Albarrán-Artahona, J.C. Laguna, I. Nalda, F.J. Muñoz-Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixidó, B. Besse, L. Mezquita, E. Auclin. Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC.

World Conference on Lung Cancer. (2023).
Project Data Sphere, RocheN/AN/A
7164Jörg EllingerUniversity Hospital BonnEvaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaJ. Saal, T. Bald, M. Eckstein, D.J. Ralser, M. Ritter, P. Brossart, V. Grünwald, M. Hölzel, J. Ellinger, N. Klümper. A0332 - On-treatment modified Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma, European Urology, Volume 83, Supplement 1, 2023, Page S483,ISSN 0302-2838.

doi: 10.1016/S0302-2838(23)00381-0
Roche1N/A
7164Jörg EllingerUniversity Hospital BonnEvaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaSaal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klümper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology.

doi: 10.1001/jamaoncol.2023.1822
Roche1466
7164Jörg Ellinger University Hospital Bonn Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaSaal J, Bald T, Eckstein M, Ralser D, Ritter M, Brossart P, Grünwald V, Hölzel M, Ellinger J, Klümper N. (2023). In the phase 2/3 IMmotion150/151 study, the Modified Glasgow Prognostic Score (mGPS) improves the imaging-only prediction of treatment response in patients with metastatic renal cell carcinoma. North Rhine-Westphalian Society for Urology.

Doi : 10.3205/23nrwgu20
RocheN/AN/A
7224Keiichi FujiwaraGynecologic Oncology Trial and Investigation Consortium (GOTIC)Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technologyMiyagi, Y., Keiichi Fujiwara, Hisanaga Nomura, Koji Yamamoto, & Robert L Coleman. (2023). Feasibility of New Method for the Prediction of Clinical Trial Results Using Compressive Sensing of Artificial Intelligence. British Journal of Healthcare and Medical Research, 10(1), 237–267.

doi : 10.14738/bjhmr.101.14061
Boehringer Ingelheim, Lilly, Roche1N/A
7232Neil OxtobyUniversity College LondonIdentification of heterogeneity in Alzheimer’s disease clinical trials using computational modellingC. Shand, N.P. Oxtoby. INVESTIGATING TREATMENT EFFECT HETEROGENEITY IN DATA-DRIVEN SUBGROUPS OF TOMMORROW. Journal of Prevention of Alzheimer’s Disease. 2023;

Abstract P004, pg. S57
TakedaN/AN/A
7321Neeraj NarulaHamilton Health SciencesA Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative ColitisWong ECL, Merat S, Monaco C, Dulai PS, Jairath V, Marshall JK, Reinisch W, Narula N. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. Dig Dis Sci. 2023 Jun;68(6):2635-2646.

doi : 10.1007/s10620-023-07956-8
Johnson & Johnson, Pfizer80
7322 Zhengfei Zhu Fudan University Shanghai Cancer Center Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasisGuo, T., Zhou, Y., Liang, F., Wang, Z., Bourbonne, V., Käsmann, L., Sundahl, N., Wu, A.J.C., Ni, J. and Zhu, Z., 2024. Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. Cancer Communications, 44(2), p.278.

Doi: 10.1002/cac2.12512
Roche20
7322 Zhengfei Zhu Fudan University Shanghai Cancer Center Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasisZhou, Y., Ni, J., Zhu, Z. and Zhang, Z., 2023. Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment.

Doi: 10.1200/JCO.2023.41.16_suppl.2032
Roche0N/A
7394, 5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersManning-Bennett AT, Cervesi J, Bandinelli P-A, Sorich MJ, Hopkins AM. Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. Biomedicines. 2023; 11(2):528.

doi : 10.3390/biomedicines11020528
Roche1N/A
7394, 5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersLee X Li, Federico Cappuzzo, Ignacio Matos, Mark A Socinski, Ashley M Hopkins, Michael J Sorich. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. The Oncologist, 2023;, oyad043.

doi: 10.1093/oncolo/oyad043
Roche193
7399Yoichi Naito National Cancer Center Hospital East Correlation of doxorubicin dose and survival in patients with soft tissue sarcoma; Data from two studies (a larger phase III study and a smaller phase II study) will be combined and analyzed.Naito, Y., Sakamaki, K., Morita, S., Mukohara, T. and Akimoto, T., 2023. 1923P Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma. Annals of Oncology, 34, pp.S1034-S1035.

Doi: 10.1016/j.annonc.2023.09.1152
Lilly0N/A
7520Malathi RamJohns Hopkins UniversityACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysisDi Stefano, L., Ram, M., Scharfstein, D. O., Li, T., Khanal, P., Baksh, S. N., ... & Freilich, D. A. (2023). Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis. Medicine, 102(23).

Doi: 10.1097/MD.0000000000033904
Bassett Medical Center, Sharp Healthcare, University of Kansas Medical Center, University of Minnesota20
7542Neeraj NarulaHamilton Health SciencesVedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect ComparisonsNarula, N., Wong, E.C.L., Dulai, P.S. et al. Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission. Dig Dis Sci (2023).

doi:  10.1007/s10620-023-07825-4
AbbVie, Takeda10
7542Neeraj NarulaHamilton Health SciencesVedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect ComparisonsWong, E.C., Dulai, P.S., Marshall, J.K., Jairath, V., Reinisch, W. and Narula, N., 2023. Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy. Inflammatory Bowel Diseases, p.izad077.

doi: 10.1093/ibd/izad077
AbbVie, Takeda00
7544Abhimanyu Mahajan Rush University Medical Center Sensory trick and benefit from botulinum toxin in cervical dystoniaAbhimanyu M, Gonzalez D A, Stebbins G T & Comella C. 2023. Therapeutic benefit of sensory trick in cervical dystonia. Movement Disorders Clinical Practice.

Doi: 10.1002/mdc3.13874
AbbVie100
7544Abhimanyu Mahajan Rush University Medical Center Sensory trick and benefit from botulinum toxin in cervical dystoniaA. Mahajan, D. Gonzalez, G. Stebbins, C. Comella. Quantifying the impact of sensory tricks on the overall severity of cervical dystonia [abstract].

Mov Disord. 2023; 38 (suppl 1)
AbbVieN/AN/A
7581Rustam Al-Shahi Salman University of Edinburgh Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH)Al-Shahi Salman R, Stephen J, Tierney JF, Lewis SC, Newby DE, Parry-Jones AR, White PM, Connolly SJ, Benavente OR, Dowlatshahi D, Cordonnier C, Viscoli CM, Sheth KN, Kamel H, Veltkamp R, Larsen KT, Hofmeijer J , Kerkhoff H, Schreuder FHBM, Shoamanesh A, Klijn CJM, Van der Worp HB. 2023. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology.

doi: 10.1016/S1474-4422(23)00315-0
Daiichi Sankyo581
7583, 5932Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer PatientsSaifi O, Bachir B, Panoff J, Poortmans P, Zeidan YH. Post-mastectomy Radiation Therapy in HER-2 Positive Breast Cancer after Primary Systemic Therapy: Pooled Analysis of TRYPHAENA and NeoSphere Trials. Radiother Oncol. 2023 Apr 6:109668.

doi : 10.1016/j.radonc.2023.109668
Roche571
7587Sudhir Sivakumaran Critical Path InstituteDevelopment of model-informed drug development tools for Alzheimer's DiseaseSudhir Sivakumaran, Yashmin Karten, Nicholas Cullen, Corissa Lau, Eileen Priest, Hazel White, Klaus Romero, Michael Irizarry. Accelerating drug development through precompetitive data sharing and collaboration in the Critical Path for Alzheimer’s Disease (CPAD) Consortium.

Abstract P0325/#231, p325.
LillyN/AN/A
7587Sudhir Sivakumaran Critical Path Institute Development of model-informed drug development tools for Alzheimer's DiseaseSivakumaran, S., Cui, Z., Priest, E., Lau, C., White, H., Irizarry, M.C., Romero, K. and Karten, Y., 2022. Development of Clinical Trial Simulation Tools for Alzheimer’s Disease through the Critical Path for Alzheimer’s Disease (CPAD) Consortium.

Alzheimer's Association International Conference. P4-642.
LillyN/AN/A
7587Sudhir Sivakumaran Critical Path Institute Development of model-informed drug development tools for Alzheimer's DiseaseSivakumaran S, Cullen N, Lau C, Priest E, White H, Irizarry M, Klein G, Romero K, Leuzy A, Karten Y. , 2023. PLANNING THE NEXT GENERATION OF ALZHEIMER’S DISEASE CLINICAL TRIALS USING DIVERSE PATIENT-LEVEL DATABASE FROM THE CRITICAL PATH FOR ALZHEIMER’S DISEASE (CPAD) CONSORTIUM. 16th Clinical Trials on Alzheimer’s Disease (CTAD) Boston, MA (USA) October 24-27, 2023. PO32. S84. Posters. J Prev Alzheimers Dis 10 (Suppl 1).

Doi: 10.14283/jpad.2022.130
LillyN/AN/A
7587Sudhir Sivakumaran Critical Path Institute Development of model-informed drug development tools for Alzheimer's DiseaseSivakumaran S, Cullen N, Lau C, Priest E, White H, Irizarry M, Klein G, Romero K, Leuzy A, Karten Y. . CRITICAL PATH FOR ALZHEIMER’S DISEASE (CPAD) CONSORTIUM: DATA-DRIVEN SOLUTIONS FOR CLINICAL TRIAL DESIGN AND INFORMED DECISION MAKING 16th Clinical Trials on Alzheimer’s Disease (CTAD). Boston, MA (USA) October 24-27, 2023. PO33. S85. Posters. J Prev Alzheimers Dis 10 (Suppl 1).

Doi: 10.14283/jpad.2022.130
LillyN/AN/A
7599Hwanhee HongDuke University Combining data sources to identify effect moderation for personalized mental health treatmentLupton Brantner, C., Quynh Nguyen, T., Tang, T., Zhao, C., Hong, H. and Stuart, E.A., 2023. Comparing Machine Learning Methods for Estimating Heterogeneous Treatment Effects by Combining Data from Multiple Randomized Controlled Trials. arXiv e-prints, pp.arXiv-2303.

Doi: 10.48550/arXiv.2303.16299
Johnson & Johnson, Lundbeck, Takeda3N/A
7606Amber Salter University of Texas Southwestern Medical Center Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple SclerosisA. Salter, S. Lancia, K. Kowalec, K. Fitzgerald, R. A. Marie. O107/355 Prevalence of Comorbidities in Phase III Clinical Trials for Disease-Modifying Therapies in Multiple Sclerosis. MSMilan2023 – Oral Presentations. Multiple Sclerosis Journal, vol. 29 no. 3_suppl. Pp 4-136. Page 82.

Doi: 10.1177/13524585231196191
Roche0N/A
7654Shirley YuUniversity of SydneyUpdate of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritisShirley PY, van Middelkoop M, Ferreira ML, Deveza L, Bierma-Zeinstra SM, Venkatesha V, Hunter DJ. The OA Trial Bank: Update of individual patient data meta-analysis of intra-articular glucocorticoids in persons with knee and hip osteoarthritis. Osteoarthritis and Cartilage Open. 2023 Apr 11:100362.

doi: 10.1016/j.ocarto.2023.100362
SanofiN/A0
7654Shirley YuUniversity of SydneyUpdate of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritisYu, S., Van Middelkoop, M., Ferreira, M., Deveza, L., Bierma-Zeinstra, S.M.A., Venkatesha, V. and Hunter, D., 2023. POS1362 THE OA TRIAL BANK: UPDATE OF INDIVIDUAL PATIENT DATA META-ANALYSIS OF INTRA-ARTICULAR GLUCOCORTICOIDS IN PERSONS WITH KNEE AND HIP OSTEOARTHRITIS.

Doi: 10.1136/annrheumdis-2023-eular.1812
Sanofi0N/A
7658Arman Sabbaghi Purdue University Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 TreatmentsJiang S., Liu B., Nei L., Sabbaghi A., Abdul Wahab A.H., Qu Y., Lyu T., Zhuang R. Is good enough good enough: A comprehensive evaluation of ICH E9 (R1) Strategies.

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. PS5C. 2023.
SanofiN/ANA
7660Shirley YuUniversity of SydneyPredictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysisYu SP, van Middelkoop M, Deveza LA, Ferreira ML, Bierma‐Zeinstra S, Zhang W, Atchia I, Birrell F, Bhagavath V, Hunter DJ. Predictors of placebo response to local (intra‐articular) therapy in osteoarthritis–an individual participant data meta‐analysis. Arthritis Care & Research. 2023 Jul 31.

doi: 10.1002/acr.25212
Sanofi100
7667Ashley HopkinsFlinders University Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumoursHopkins, A.M., Modi, N. and Sorich, M.J., 2023. Is there a harmonised standard to oncology trial data provision in data sharing initiatives?.

Doi: 10.1200/JCO.2023.41.16_suppl.e13645
AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, Takeda0N/A
7667Ashley HopkinsFlinders University Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumoursHopkins AM, Modi ND, Abuhelwa AY, et al. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncol. 2023.

doi: 10.1001/jamaoncol.2023.3996
AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, Takeda672
7743Caroline Quach CHU Sainte-Justine Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-AnalysisKiely, M., Tadount, F., Lo, E., Sadarangani, M., Wei, S.Q., Rafferty, E., Quach, C. and MacDonald, S.E., 2023. Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. J Epidemiol Community Health.

Doi: 10.1136/jech-2023-220781
Sanofi2960
7772Neeraj NarulaHamilton Health SciencesCombined Histologic and Endoscopic Endpoints in Ulcerative ColitisEmily C L Wong, BHSc, Parambir S Dulai, MD, Badar Hasan, MD, John K Marshall, MD, MSc, FRCPC, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH, FRCPC. Combined Histologic and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared to Endoscopic Improvement Alone in Ulcerative Colitis: A Post-hoc Analysis of the VARSITY study. Journal of Crohn's and Colitis, 2023;, jjad033.

doi: 10.1093/ecco-jcc/jjad033
Takeda00
7797Jörg EllingerUniversity Hospital BonnEvaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinomaJonas Saal, Tobias Bald, Markus Eckstein, Manuel Ritter, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper. Early CRP kinetics predicts immunotherapy response in NSCLC in the phase III OAK trial. JNCI Cancer Spectrum, 2023;, pkad027.

doi : 10.1093/jncics/pkad027
Roche95
7809David James PinatoImperial College, LondonThe predictive role of concomitant antibiotics in patients treated with immunotherapy or oral treatment for unresectable hepatocellular carcinoma (HCC)Claudia A.M. Fulgenzi, Cian Murphy, Antonio D’Alessio, Bernhard Scheiner, Matthias Pinter, Alessio Cortellini, David J. James Pinato. Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study. J Clin Oncol 41, 2023 (suppl 4; abstr 597).

doi: 10.1200/JCO.2023.41.3_suppl.597.
Roche0N/A
7817Neeraj Narula Hamilton Health Sciences Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic EsophagitisWong, E.C., Gleave, A.L., Marshall, J.K. and Narula, N., Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis. European Journal of Gastroenterology & Hepatology, pp.10-1097.

Doi: 10.1097/MEG.0000000000002623
GlaxoSmithKline00
7822Linbin Lu The 900th Hospital of PLA Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatmentLu, L., Zheng, P., Pan, Y., Huang, S., Shao, E., Huang, Y., Wang, X., Chen, Y., Cuo, G., Yang, H. and Guo, W., 2023. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study. British Journal of Cancer, 129(4), pp.620-625.

Doi: 10.1038/s41416-023-02334-7
Roche02
7823Marc Carrier University of Ottawa Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review Mallity, C., Collins, E., Siegal, D., Wang, T., Carrier, M. and Xu, Y., 2023. IMPACT OF ANTICOAGULANTS FOR ARTERIAL THROMBOEMBOLISM PREVENTION AMONG AMBULATORY CANCER PATIENTS BY PRIMARY TUMOUR SITE: SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Diabetes, 47(7), pp.S209-S210.

Doi: 10.1016/j.jcjd.2023.10.390
GlaxoSmithKline, Sanofi0N/A
7823Marc Carrier University of Ottawa Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review Mallity, C., Collins, E., Siegal, D., Wang, T., Carrier, M. IMPACT OF ANTICOAGULANTS FOR ARTERIAL THROMBOEMBOLISM PREVENTION AMONG AMBULATORY CANCER PATIENTS BY PRIMARY TUMOUR SITE: SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Cardiology, Volume 39, Issue 10, S252 - S253.

doi: 10.1016/j.cjca.2023.06.405
GlaxoSmithKline, Sanofi0N/A
7856Evandro de AzambujaInstitut Jules BordetMetastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survivalDebien, V., Agostinetto, E., Bruzzone, M., Ceppi, M., Molinelli, C., Branco, D.M., Jacobs, F., Marta, G.N., Lambertini, M. and de Azambuja, E., 2023. 228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial. ESMO Open, 8(1).

doi.org/10.1016/j.esmoop.2023.101417
Roche0N/A
7858Jie Zha Xiamen University Retrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patientsZha, J., Chen, Q., Zhang, W., Jing, H., Ye, J., Yu, H., Yi, S., Li, C., Zheng, Z., Xu, W. and Li, Z., 2023. Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma. Blood, 142(Supplement 1), pp.3048-3048.

Doi: 10.1182/blood-2023-182812
Roche00
7868Anne-Marie Dingemans Erasmus MC University Medical Center Predictive clinical characteristics for weight gain in patients treated with alectinibSikkema, B.J., Baart, S.J., Paats, M.S., Smit, E.F., Schols, A.M., Mathijssen, R.H., van Rossum, E.F. and Dingemans, A.C., 2023. 1367P Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453. Annals of Oncology, 34, p.S785.

Doi : 10.1016/j.annonc.2023.09.2400
Roche0N/A
7875Marco ValgimigliCardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative)Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AÅ, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105.

doi: 10.1016/j.jacc.2023.04.051
Sanofi3216
8325Xiaodan TangNorthwestern UniversityDoes scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response TheoryTang, X., Schalet, B.D., Peipert, J.D. and Cella, D., 2023. Does scoring method impact estimation of significant individual changes assessed by patient-reported outcome measures? Comparing Classical Test Theory versus Item Response Theory. Value in Health.

doi:10.1016/j.jval.2023.06.002
Abbvie00
8347Hong Jae Chon CHA Bundang Medical Center Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabSong, Y.S., Yang, H., Kang, B., Cheon, J., Kim, I., Kim, H., Lee, W.S., Sang, Y.B., Jung, S., Lim, H.Y. and Gaillard, V.E., 2023. Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma.

Doi: 10.1159/000531182
Roche0N/A
8347Hong Jae Chon CHA Bundang Medical Center Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabSong, Y.S., Yang, H., Kang, B., Cheon, J., Kim, I., Kim, H., Lee, W.S., Sang, Y.B., Jung, S., Lim, H.Y. and Gaillard, V.E., 2023. 993P - Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma.

Annals of Oncology (2023) 34 (suppl_2): S594-S618.

RocheN/AN/A
8542João Sérgio NevesFaculty of Medicine of University of Porto Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition UseNeves, J.S., Borges-Canha, M., Vasques-Nóvoa, F., Green, J.B., Leiter, L.A., Granger, C.B., Carvalho, D., Leite-Moreira, A., Hernandez, A.F., Del Prato, S. and McMurray, J.J., 2023. GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with Type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp.517-525.

Doi: 10.1016/j.jacc.2023.05.048
GlaxoSmithKline121
8555Gijsbert StoetUniversity of EssexEffects of exercise on blood glucose levels, food intake and insulin use in adult T1D patientsStoet, G. and Holt, R.I., 2023. Characteristics of People with Optimally-Managed Type 1 Diabetes. Diabetes Epidemiology and Management, p.100153.

doi: 10.1016/j.deman.2023.100153
Jaeb Center for Health Research Foundation, Inc.0N/A
8559Dag AarslandKing’s College LondonPredicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine AntidepressantsXue L, Bocharova M, Young AH, Aarsland D. G18 CLINICAL FACTORS AFFECTING COGNITIVE IMPROVEMENT OF VORTIOXETINE AND DULOXETINE IN ELDERLY PATIENTS WITH MAJOR DEPRESSIVE DISORDER.

BAP2023_abstract book, pg A113.
LundbeckN/AN/A
8699Niklas KlümperUniversity Hospital BonnEvaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancersSaal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klümper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology.

doi : 10.1016/j.euo.2023.11.005
Roche51
8700Leo Buckley Brigham and Women's Hospital Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatmentAlfehaid L, Alkhezi O, Buckley L, Libby P, Desai A, Tawifk Y, Shah A. COLCHICINE, DRUG-DRUG INTERACTIONS AND GASTROINTESTINAL ADVERSE EFFECTS. American College of Clinical Pharmacy.

Session IV. 2023.
Montreal Heart InstituteN/AN/A

2022

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetrics ScorePubMed Citation Total
3369Michael WardNational Institutes of Health (NIH) Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing SpondylitisWang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022;5(3):e222312.

doi: 10.1001/jamanetworkopen.2022.2312
AbbVie, Pfizer
327
4115Amir MahabadiUniversity Hospital Essen, West German Heart and Vascular Center Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trialsL Vogel, I Dykun, P Raggi, A Schmermund, T Rassaf, A Mahabadi. High- vs. low-intensity statin therapy and changes in coronary artery calcification density after one year. European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.209.

doi: 10.1093/eurheartj/ehac544.209
Pfizer1N/A
4116Sharon StraussSt. Michael’s HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisVeroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012.

doi: 10.1136/bmjopen-2021-053012
AbbVie5343
4120Merryn VoyseyUniversity of Oxford The immunogenicity and sero-efficacy of pneumococcal vaccinesShuo Feng, Julian Higgins, Maria Knoll, Julie Mclellan, Kim Muholland, Nicola Pidduck, Andrew Pollard, Beth Temple, Merryn Voysey. COMPARISON OF IMMUNOGENICITY AND SEROEFFICACY BETWEEN TEN- AND THIRTEEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINES – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.

ESPID-2022-Abstracts-Book. Page 294 PD103 / #743.
PfizerN/AN/A
4316Martin OkunFort HealthcareGeospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis.Okun TSD, Okun MM. No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated. Journal of Psoriasis and Psoriatic Arthritis. January 2022.

doi: 10.1177/24755303221079810
AbbVie2N/A
4326John MarkmanUniversity of RochesterPhenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical InjuryGewandter JS, Sohn MB, De Guzman R, Frazer ME, Chiodo V, Sharma S, Geha P, Markman JD. Predicting treatment response with sensory phenotyping in post-traumatic neuropathic pain. Pain Med. 2022 Mar 21:pnac045. PMID: 35312012.

doi: 10.1093/pm/pnac045
Pfizer141
4326John MarkmanUniversity of Rochester Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical InjuryOlaposi Peters, John Markman, Michael Sohn, Rachel De Guzman, Maria Frazer, Valerie Chiodo, Sonia Sharma, Paul Geha, Jennifer Gewandter. Predicting treatment response with sensory phenotyping in posttraumatic
neuropathic pain.

CPS 2022 Book of Abstracts Final, page 277.
PfizerN/AN/A
4329Shomron Ben-HorinSun Yatsen 1st affiliated HospitalEfficacy of biologic drugs in short-duration versus long-duration inflammatory bowel diseaseShomron Ben-Horin, Lena Novack, Ren Mao, Jing Guo, Yue Zhao, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi, Yehuda Chowers, Laurent Peyrin-Biroulet, Jean Frederic Colombel, Gilaad G. Kaplan, Min-hu Chen. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology, 2021, ISSN 0016-5085.

doi: 10.1053/j.gastro.2021.10.037
AbbVie, Biogen, Johnson & Johnson, Takeda, UCB
3618
4921Tim BrümmendorfUniversity Hospital AachenEntropy-based Biomarkers for individualized response on Bosutinib treatment in chronic phase CMLEsfahani, Ali, Susanne Isfort, Tim Brümmendorf, and Andreas Schuppert. Entropy-based Biomarkers for Individualized Response on Bosutinib Treatment in Chronic Phase CML. OSF Preprints. March 1, 2022.

doi:10.31219/osf.io/bu2qy
Pfizer
1N/A
4922, 3274Diane van der WoudeLeiden University Medical CenterEffect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisTakase-Minegishi K, Böhringer S, Nam J, Kaneko Y, Behrens F, Saevarsdottir S, Detert J, Leirisalo-Repo M, van der Heijde D, Landewé R, Ramiro S, van der Woude D. The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).

https://acrabstracts.org/abstract/the-impact-of-autoantibodies-rf-and-acpa-on-the-efficacy-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-meta-analysis-of-randomized-controlled-trials/.
AbbVie, PfizerN/AN/A
5086Junko TakeshitaUniversity of PennsylvaniaA Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic DiseasesSevagamoorthy A, Sockler P, Akoh C, Takeshita J. Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. J Dermatolog Treat. 2022 Aug 31:1-12

doi : 10.1080/09546634.2022.2114783
AbbVie, Lilly, Regeneron144
5163Susan BatesColumbia University Medical CenterAssessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial dataCeline Yeh, Mengxi Zhou, Keith Sigel, Gayle Jameson, Ruth White, Rachael Safyan, Yvonne Saenger, Elizabeth Hecht, John Chabot, Stephen Schreibman, Béata Juzyna, Marc Ychou, Thierry Conroy, Tito Fojo, Gulam A Manji, Daniel Von Hoff, Susan E Bates. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. The Oncologist, 2022.

doi : 10.1093/oncolo/oyac217
Bristol Meyers Squibb10
5165Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostatGhang B, Lee JS, Choi J, et al. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open 2022;8:e001944

doi: 10.1136/rmdopen-2021-001944
Takeda
55
5207Fasihul KhanUniversity of NottinghamA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosisKhan FA, Stewart I, Moss S, Fabbri L, Robinson KA, Johnson SR, Jenkins RG. Three-Month FVC Change: A Trial Endpoint for IPF Based on Individual Participant Data Meta-Analysis. Am J Respir Crit Care Med. 2022 Jan 12.

doi: 10.1164/rccm.202109-2091OC
BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche
104
5291Sarah NevittUniversity of LiverpoolAntiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysisNevitt SJ, Sudell M, Cividini S, Marson AG, Tudur Smith C. Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD011412.

doi: 10.1002/14651858.CD011412.pub4
UCB4014
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning ApproachDuong, S.Q., Crowson, C.S., Athreya, A., Atkinson, E.J., Davis, J.M., Warrington, K.J., Matteson, E.L., Weinshilboum, R., Wang, L. and Myasoedova, E. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Res Ther 24, 162 (2022).

doi: 10.1186/s13075-022-02851-5
Roche, UCB16
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning ApproachDuong S, Crowson CS, Athreya A, et al. POS0514 PREDICTION OF RESPONSE TO METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A MACHINE LEARNING APPROACH USING CLINICAL TRIAL DATA. Annals of the Rheumatic Diseases 2022;81:513-514.

doi:10.1136/annrheumdis-2022-eular.891
Roche, UCB16
5456Terina MartinezCritical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy R. Belfiore-Oshan, V. Aggarwal, S. Sivakumaran, D. Corey, C. Ollivier, K. Romero, K. Vandenborne, S. Kim, J. Morales, K. Lingineni, T. Martinez.
VP.85. C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy. Neuromuscular Disorders, Volume 32, Supplement 1. 2022. Page S128.

doi: 10.1016/j.nmd.2022.07.359
CureDuchenneN/AN/A
5456Terina MartinezCritical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy Varun Aggarwal, Rhoda Muse, Sarah Kim, Jackson Burton, Diane Corey, Lauren Quinlan, Klaus Romero, Ramona Belfiore-Oshan, Terina Martinez. Multivariate Joint Models to Predict Clinically Meaningful Decline in Duchenne Muscular Dystrophy as measured by NSAA Using Timed Function Test Trajectories.

ACoP13 (2022) STPM-328.
CureDuchenneN/AN/A
5812Yougen WuThe Fifth People's Hospital of Shanghai, Fudan UniversityDevelopment and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitorsWu Y, Zhu W, Wang J, Liu L, Zhang W, Wang Y, Shi J, Xia J, Gu Y, Qian Q, Hong Y. Using machine learning for mortality prediction and risk stratification in atezolizumab-treated cancer patients: Integrative analysis of eight clinical trials. Cancer Med. 2022 Jul 24.

doi: 10.1002/cam4.5060
Roche25
5853Florian NaudetCHU RennesData-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment ReportsSiebert, M., Gaba, J., Renault, A. et al. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports. BMC Med 20, 177 (2022).

doi:10.1186/s12916-022-02377-2
AbbVie303
5869Alexandra FreemanUniversity of CambridgeMeta-analysis of the adverse effects of trastuzumab in women with breast cancerJackson, C., Finikarides, L. and Freeman, A., 2022. The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis.

doi: 10.1371/journal.pone.0275321
Roche43
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersEugene Tan, Ahmad Y. Abuhelwa, Sarah Badaoui, Natansh D. Modi, Michael D. Wiese, Ross A. McKinnon, Michael J. Sorich and Ashley M. Hopkins. Association Between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. 1 Jan, 2021 : 1

doi: 10.3233/BLC-211613
Roche3N/A
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersBadaoui S, Shahnam A, McKinnon RA, Abuhelwa AY, Sorich MJ, Hopkins AM. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy. Transl Lung Cancer Res 2022;11(3):432-439.

doi: 10.21037/tlcr-21-9385
Roche27
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersHopkins, A. M., Badaoui, S., Kichenadasse, G., Karapetis, C. S., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2022). Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. Journal of Thoracic Oncology.

doi: https://doi.org/10.1016/j.jtho.2022.02.003
Roche1314
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersAbuhelwa AY, Bellmunt J, Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM. C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab. Front Oncol. 2022 Aug 1;12:918993.

doi: 10.3389/fonc.2022.918993
Roche53
5902Thrasyvoulos TzellosNorland University HospitalDevelopment and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativaThrasivoulos Tzellos Et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022 Oct 2.

doi: 10.1111/jdv.18632. Online ahead of print.
AbbVie38
5902Thrasyvoulos TzellosNorland University HospitalDevelopment and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativaK. R. van Straalen, T. Tzellos, A. Alavi, F. Benhadou, C. Cuenca-Barrales, M. Daxhelet, M. Daoud, O. Efthymiou, E. J. Giamarellos-Bourboulis, P. Guillem, W. Gulliver, G. B. Jemec, A. Katoulis, A. Koenig, E. Lazaridou, M. Lowes, A. V. Marzano, L. Matusiak, A. Molina-Leyva, C. Moltrasio, A. Pinter, C. Potenza, E. P. Prens, J. Romaní, D. M. Saunte, C. J. Sayed, N. Skroza, D. Stergianou, J. C. Szepietowski, A. Trigoni, E. Vilarrasa, H. H. van der Zee, A. Kyrgidis, C. C. Zouboulis. (2022), 11th EHSF Conference 2022 Abstracts. Exp Dermatol, 31: 40-125. S-01-12 – Development and validation of an IHS4 dichotomous outcome to assess treatment effect. (p.47).

Doi: 10.11111/exd.14557
AbbVie3N/A
5933Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritisManning-Bennett, A. T., Hopkins, A. M., Sorich, M. J., Proudman, S. M., Foster, D. J. R., Abuhelwa, A. Y., & Wiese, M. D. (2022). The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis – a pooled analysis of five randomised controlled trials. Therapeutic Advances in Musculoskeletal Disease.

doi:10.1177/1759720X221111613
Roche24
5933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritisDaraghmeh DN, Hopkins AM, King C, Abuhelwa AY, Wechalekar MD, Proudman SM, Sorich MJ, Wiese MD. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2022 Jun 22:keac357.

doi : 10.1093/rheumatology/keac357
Roche2450
5933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritisManning-Bennett A, Hopkins A, Sorich M, Proudman S, Foster D, Abuhelwa A, Wiese M. The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis [abstract]. Arthritis Rheumatol. 20 22; 74 (suppl 9).

https://acrabstracts.org/abstract/the-association-of-cardiovascular-comorbidities-with-remission-in-rheumatoid-arthritis-patients-undergoing-treatment-with-baricitinib-and-conventional-synthetic-dmards-a-post-hoc-analysis/
LillyN/AN/A
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Zhou J, Yang J, Wang H, et al. Machine learning based on blood biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy. Annals of Oncology (2022) 33 (suppl_2): S27-S70.

doi: 10.1016/j.annonc.2022.02.069
Roche0N/A
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Ma, SC., Bai, X., Guo, XJ., Liu, L., Xiao, LS., Lin, Y., Tan, JL., Cai, XT., Wen, YX., Ma, H., Fu, QJ., Leng, MX., Zhang, YP., Long, LL., Guo, ZQ., Wu, DH., Zhou, JG., Dong, ZY. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Med 20, 120 (2022).

doi: 10.1186/s12916-022-02315-2
Roche55
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials. Jian-Guo Zhou, Xiaofei Chen, Ada Hang-Heng Wong, Haitao Wang, Fangya Tan, Si-Si He, Gang Shen, YunJia Wang, Ruihong Wang, Shamus R. Carr, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, David S. Schrump, and Udo S Gaipl. Journal of Clinical Oncology 2022 40:16_suppl, e21113-e21113.

doi: 10.1200/JCO.2022.40.16_suppl.e21113.
Roche1N/A
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Zhou, J.G., Wong, A.H.H., Wang, H., Tan, F., Chen, X., Jin, S.H., He, S., Shen, G., Wang, Y.J., Frey, B. and Fietkau, R. Elucidation of the application of blood test biomarkers to predict immune-related adverse events (irAEs) in atezolizumab-treated NSCLC patients by using machine learning methods. Frontiers in Immunology, p.3081.

doi: 10.3389/fimmu.2022.862752
Roche47
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Zhou J, Wong A, Wang H, Jin S, Tan F, Chen Y, He S, Shen G, Frey B, Fietkau R, Hecht M, Carr S, Wang R, Shen B, Schrump D, Ma H and Gaipl US(2022) Definition of a new blood cell count (BCT) score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials. Front. Immunol. 13:961926.

doi:10.3389/fimmu.2022.961926
Roche21
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical University Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Zhou, Jian-Guo and Yang, Jie and Wang, Haitao and Wong, Ada Hang-Heng and Tan, Fangya and Chen, Xiaofei and he, sisi and Shen, Gang and Wang, Yun-Jia and Frey, Benjamin and Fietkau, Rainer and Hecht, Markus and Zhong, Wen-Zhao and Ma, Hu and Gaipl, Udo. Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy.

DOI : 10.2139/ssrn.4214527
Roche1N/A
5945Neeraj NarulaMcMaster UniversityPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITYWong ECL, Dulai PS, Narula N. Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Gui et al. Gut. 2022 Jun 7. gutjnl-2022-327661.

doi: 10.1136/gutjnl-2022-327661
Takeda20
5951, 4543Mathilde NijkeuterUMC UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolismde Winter, M.A., Uijl, A., Büller, H.R., Carrier, M., Cohen, A.T., Hansen, J.B., Kaasjager, K.H., Kakkar, L.A.K., Middeldorp, S., Raskob, G.E. and Sørensen, H.T., 2022. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis. Journal of Thrombosis and Haemostasis.

doi: 10.1016/j.jtha.2022.11.013
Daiichi Sankyo0N/A
5959John DennisUniversity of Exeter Medical SchoolStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetesDennis, J.M., Young, K.G., McGovern, A.P., Mateen, B.A., Vollmer, S.J., Simpson, M.D., Henley, W.E., Holman, R.R., Sattar, N., Pearson, E.R. and Hattersley, A.T., 2022. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), pp.e873-e883.

doi: 10.1016/S2589-7500(22)00174-1
Boehringer Ingelheim345
5984David BakerQueen Mary University of LondonExploring possibilities to improve the risk benefit balance through analysis of the ocrelizumab phase II extension studyBaker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2022). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 57, 103448.

doi: 10.1016/j.msard.2021.103448
Roche
2714
6004Lily LimUniversity of ManitobaIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change TreatmentLim LSH, Shobhan S, Lokku A, Ringold S, Pullenayegum E. Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials. Pediatr Rheumatol Online J. 2022 Jul 30;20(1):57.

doi: 10.1186/s12969-022-00719-1
Roche10
6004Lily LimUniversity of ManitobaIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change TreatmentLim, L. S. H., Lokku, A., Pullenayegum, E., & Ringold, S. Probability of Response in the First 16 Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials. Arthritis Care & Research.

doi: 10.1002/acr.25003
Roche11N/A
6006Nicholas WhiteMahidol UniversityA Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19Chotsiri, P., Tarning, J., Hoglund, R.M., Watson, J. and White, N.J. (2022), Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. Clin Pharmacol Ther.

doi:10.1002/cpt.2665
Pfizer91
6007Judith GoldsteinJohns Hopkins School of MedicineNational Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD)Judith E. Goldstein, Chris Bradley, Alden L. Gross, Marylou Jackson, Neil Bressler, Robert W. Massof; The NEI VFQ-25C: Calibrating Items in the National Eye Institute Visual Function Questionnaire-25 to Enable Comparison of Outcome Measures. Trans. Vis. Sci. Tech. 2022;11(5):10.


doi: 10.1167/tvst.11.5.10.
Roche26
6041Neeraj NarulaHamilton Health SciencesHistologic Predictors of Endoscopic Healing in Crohn's DiseaseEmily C L Wong, BHSc, Arif Yusuf, MD, Jagoda Pokryszka, MD, Parambir S Dulai, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease. Inflammatory Bowel Diseases. 2022, izac157.

doi: 10.1093/ibd/izac157, doi: 10.1093/ibd/izac208
AbbVie01
6062Alexander MeiselUniversity Hospital of Zurich Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-CombinationsA. Meisel, M.T. Mark, A. Haider, L. Holer, S. Hayoz, C. Gebhard, S. Bengs, V. Treyer, S.I. Rothschild, M.J. Hochmair, D.R. Gandara, F. Cappuzzo, M. Reck, F. Stenner-Liewen, R.A.F. von Moos. 1051P - Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and hemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC).

Annals of Oncology (2022) 33 (suppl_7): S 448-S554.
RocheN/AN/A
6494Maria Alice FranzoiJules Bordet InstituteImplications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant settingFranzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. 2022 Jan 25.

doi: 10.1007/s10549-022-06525-3.
Lilly
13
6494Maria Alice FranzoiJules Bordet InstituteImplications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant settingMaria Alice Franzoi, Matteo Lambertini, Marcello Ceppi, Marco Bruzonne, Evandro de Azambuja. Abstract P5-13-07: Implications of body mass index (BMI) on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting. Cancer Res, 15 February 2022; 82 (4_Supplement): P5–13–07.

doi: 10.1158/1538-7445.SABCS21-P5-13-07
Lilly
1N/A
6496Neeraj NarulaHamilton Health SciencesEndoscopic Disease Severity and Patient Reported Outcomes in Crohns DiseaseCara Pray, MD, Emily C L Wong, BHSc, Achuthan Aruljothy, MDCM, Parambir S Dulai, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis. Inflammatory Bowel Diseases, 2022. izac210

doi : 10.1093/ibd/izac210
AbbVie, Johnson & Johnson00
6499, 5323, 5289Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancerN.D. Modi, N.O. Danell, R.N.A. Perry, A.Y. Abuhelwa, A. Rathod, S. Badaoui, R.A. McKinnon, M. Haseloff, A. Shahnam, S.M. Swain, M. Welslau, M.J. Sorich, A.M. Hopkins, "Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer", ESMO Open, Volume 7, Issue 3, 2022, 100475.

doi:10.1016/j.esmoop.2022.100475
Roche763
6532Odelia CooperCedars-Sinai Medical CenterA study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumorsOdelia Cooper, Sungjin Kim. ODP643 Metabolic Effects of Growth Hormone Replacement in Craniopharyngioma and Pituitary Adenoma Patients: Analysis of the Hypopituitary Control and Complications Study (HypoCCS) Database. Journal of the Endocrine Society, Volume 6, Issue Supplement_1, November-December 2022, Page A521.

doi: 10.1210/jendso/bvac150.1085
Lilly1N/A
6543Andreas MeidHeidelberg University HospitalReproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) – can ML methods support the validity of conventional TGI metrics?Meid, A., Gerharz, A., Groll, A. Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility. CPT: Pharmacometrics & Systems Pharmacology. 2022 Feb 01.

doi: 10.1002/psp4.12761
Roche
23
6601Dan TurnerShaare Zedek Medical CenterAdaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial dataDotan Yogev, MD, Bram Verstockt, MD, PhD, Axel Dignass, MD, PhD, Gili Focht, MSc, MBA, Ohad Atia, MD, Iris Dotan, MD, PhD, Severine Vermeire, MD, PhD, Dan Turner, MD, PhD. The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn’s Disease. Inflammatory Bowel Diseases, 2022;. izac235.

doi : 10.1093/ibd/izac235
AbbVie10
6632Luca ValerioUniversity Medical Center of the Johannes Gutenberg-University MainzHealthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in venous thromboembolism (VTE) studyFarmakis IT, Barco S, Mavromanoli AC, Agnelli G, Cohen AT, Giannakoulas G, Mahan CE, Konstantinides SV, Valerio L. Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry. J Am Heart Assoc. 2022 Oct 18;11(20):e027514.

doi : 10.1161/JAHA.122.027514
Daiichi Sankyo54
6633Luca ValerioUniversity Medical Center MainzPerformance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer studyFarmakis IT, Barco S, Mavromanoli AC, Konstantinides SV, Valerio L. Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study. JACC CardioOncol. 2022 Nov 15;4(4):507-518.

doi: 10.1016/j.jaccao.2022.07.008
Daiichi Sankyo95
6710Gus SlotmanInspira Health NetworkIdentifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced MortalityKelter, David MD; Slotman, Gus J MD, FACS. Smart Identifies Dichotomous Drotrecogin Alfa Activated Treatment Effects on Mortality in Prowess Shock. Journal of the American College of Surgeons: November 2022 - Volume 235 - Issue 5 - p S296.

doi: 10.1097/01.XCS.0000895332.83940.b8
Lilly1N/A
6732Yung-Chuan HuangFu Jen Catholic University HospitalDecision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation PatientsHuang Y-C, Cheng Y-C, Jhou M-J, Chen M, Lu C-J. Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—A Post Hoc Analysis. Journal of Personalized Medicine. 2022; 12(5):756.

doi:10.3390/jpm12050756
Boehringer Ingelheim19
6734Andreas SuhrbierQIMR Berghofer Medical Research InstituteThe K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humansBishop CR, Dumenil T, Rawle DJ, Le TT, Yan K, et al. Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. (2022). PLOS Pathogens 18(9): e1010867.

Doi: 10.1371/journal.ppat.1010867
Hannover Medical School410
6765Dan HanleyJohns Hopkins UniversityPandemic response COVID-19 Research Collaboration PlatformDi Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, Baksh SN, McBee N, Gruber J, Gildea MR, Clark MR, Goldenberg NA, Bennani Y, Brown SM, Buckel WR, Clement ME, Mulligan MJ, O'Halloran JA, Rauseo AM, Self WH, Semler MW, Seto T, Stout JE, Ulrich RJ, Victory J, Bierer BE, Hanley DF, Freilich D. Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One. 2022 Sep 29;17(9):e0273526.

Doi: https://doi.org/10.1371/journal.pone.0273526
NYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans335
6866Andy LimMonash UniversityMeta-analysis of early stroke recurrence rate in minor strokeA. Lim, H. Ma, C. Johnson, S. Singhal, S. Muthusamy, Y. Wang, Y. Pan, S. Coutts, A. Ois, M.K Kapral, M. Knoflach, L.J Woodhouse, P.M Bath, T Phan. Ninety-day stroke recurrence rate in minor stroke: a meta-analysis of randomized trials and observational studies. European Stroke Journal. 2022;7(1_suppl):3-545. European Stroke Organisation Conference (ESOC) 2022 Abstract Book, O084 / 129 page 48.

doi: 10.1177/23969873221087559.
AstraZeneca10N/A
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesDing, W.Y., Calvert, P., Gupta, D. et al. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. Clin Res Cardiol (2022).

doi:10.1007/s00392-022-02022-1
Boehringer Ingelheim47
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesRomiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022 Aug 29.

doi: 10.1055/s-0042-1756355
Boehringer Ingelheim2614
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesDing WY, Lane DA, Gupta D, Huisman MV, Lip GYH, GLORIA‐AF Investigators. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry. J Am Heart Assoc. 2022 Aug 2;11(15):e026410.

doi : 10.1161/JAHA.122.026410.
Boehringer Ingelheim145
7077Neeraj NarulaHamilton Health SciencesDominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s DiseaseWong, EC, Dulai, PS, Marshall, JK, Jairath, V, Reinisch, W, Narula, N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Aliment Pharmacol Ther. 2022; 00: 1– 9.

doi: 10.1111/apt.16805
AbbVie, Johnson & Johnson
80
7077Neeraj NarulaHamilton Health SciencesDominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s DiseaseN Narula, C Pray, E Wong, J F Colombel, J Marshall, M Daperno, W Reinisch, P Dulai. DOP16 Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD). Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i065–i066.

doi: 10.1093/ecco-jcc/jjab232.055
AbbVie, Johnson & Johnson
1N/A
7077Neeraj NarulaHamilton Health SciencesDominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s DiseaseNeeraj Narula, Cara Pray, Emily C L Wong, Jean-Frederic Colombel, John K Marshall, Marco Daperno, Walter Reinisch, Parambir S Dulai. Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis, 2022;, jjac018,.

doi: 10.1093/ecco-jcc/jjac018
AbbVie, Johnson & Johnson
63
7126Alessio CortelliniImperial College LondonThe predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancerDifferential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial. Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, Claudia A.M. Fulgenzi, Alfredo Addeo, Giuseppe Luigi L. Banna, and David J. James Pinato. Journal of Clinical Oncology 2022 40:16_suppl,

9056-9056. doi:10.1200/JCO.2022.40.16_suppl.9056
Roche1N/A
7126Alessio CortelliniImperial College LondonThe predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancerCortellini, A., Ricciuti, B., Borghaei, H., Naqash, A.R., D'Alessio, A., Fulgenzi, C.A.M., Addeo, A., Banna, G.L. and Pinato, D.J. (2022), Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer.

doi: 10.1002/cncr.34348
Roche2411
7158Neeraj NarulaHamilton Health SciencesPatient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative ColitisEmily Chu Lee Wong, Badar Hasan, Parambir S. Dulai, John K. Marshall, Walter Reinisch & Neeraj Narula. (2022). End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. Scandinavian Journal of Gastroenterology.

DOI: 10.1080/00365521.2022.2105169
Takeda11
7159James SignorovitchAnalysis GroupAssociations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD)Associations Between Steroid Treatment and Clinical Outcomes Among Non-ambulatory Patients with Duchenne Muscular Dystrophy (DMD) (P1-1.Virtual). Craig McDonald, Oscar Mayer, Kan Hor, Jessica Marden, Jonathan Freimark, Henry Lane, Adina Zhang, Molly Frean, Claudio Santos, Richard Able, James Signorovitch. Neurology May 2022, 98 (18 Supplement) 1348

https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.1348
CureDuchenneN/AN/A
7159James SignorovitchAnalysis GroupAssociations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD)Associations Between Deflazacort Versus Prednisone/Prednisolone and Markers of Disease Progression in Clinically Important Subgroups of Patients with Duchenne Muscular Dystrophy (P1-1.Virtual). Craig McDonald, Jessica Marden, Henry Lane, Adina Zhang, Ha Nguyen, Claudio Santos, Richard Able, James Signorovitch. Neurology May 2022, 98 (18 Supplement) 1437

https://doi.org/10.1212/WNL.98.18_supplement.1437
CureDuchenneN/AN/A
7159James SignorovitchAnalysis GroupAssociations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD)McDonald CM, Mayer OH, Hor KN, Miller D, Goemans N, Henricson EK, Marden JR, Freimark J, Lane H, Zhang A, Frean M, Trifillis P, Koladicz K, Signorovitch J; PRO-DMD-01 consortium investigators. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2023;10(1):67-79.

doi : 10.3233/JND-221575.
CureDuchenne11
7164Jörg EllingerUniversity Hospital BonnEvaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaSaal J, Bald T, Hölzel M, Ritter M, Brossart P, Ellinger J, Klümper N. In the phase 3 IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. Ann Oncol. 2022 Jun 15:S0923-7534(22)01730-6.


doi: 10.1016/j.annonc.2022.06.003
Roche104
7164Jörg Ellinger University Hospital Bonn Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaSaal J, Bald T, Hölzel M, Ritter M, Brossart P, Ellinger J, Klümper N.
P229 Der modifizierte Glasgow Prognostic Score (mGPS) sagt das Überleben in Patienten mit metastasiertem Nierenzellkarzinom in der Phase III IMmotion151 Studie besser voraus als der IMDC score. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022. Oncol Res Treat 27 September 2022; 45 (Suppl. 2): 5–346, Page 318.

doi: 10.1159/000526456
Roche00
7225Neeraj NarulaHamilton Health SciencesEarly vs. Delayed Response to Vedolizumab in Ulcerative ColitisNarula, Neeraj MD, MPH, FRCPC; Wong, Emily C.L. BHSc; Marshall, John K. MD, MSc, FRCPC; Jairath, Vipul MD, PhD; Dulai, Parambir S. MD; Reinisch, Walter MD, PhD. Long-term Outcomes of Early Versus Delayed Responders to Vedolizumab and Adalimumab: A Post-hoc Analysis of VARSITY. The American Journal of Gastroenterology: September 1, 2022 - Volume - Issue - 10.14309/ajg.0000000000001987

doi : 10.14309/ajg.0000000000001987
Takeda132
7225Neeraj NarulaHamilton Health SciencesEarly vs. Delayed Response to Vedolizumab in Ulcerative ColitisZ. Alhashimalsayed, E. C.L. Wong, W. Reinisch, N. Narula. MP444 SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY. United European Gastroenterology Journal 2022; 10 (Supplement 8), October 2022. Moderated Posters p276/277.

doi : 10.1002/ueg2.12294
Takeda2N/A
7241Frederick ReimherrPsychiatric and Behavioral Solutions, LLCRetrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by BrexpiprazoleReimherr, Frederick W.; Gift, Thomas E.; Steans, Tammy A.; Reimherr, Matthew L.; Rosenberg, Leon I.; Wilson, Melissa; Marchant, Barrie K. The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology: August 17, 2022 - Volume - Issue - 10.1097/JCP.0000000000001592.

doi : 10.1097/JCP.0000000000001592.
Otsuka50
7245Manabu TakakiOkayama UniversityClinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in JapanNozomu Hashimoto, Hiroshi Habu, Soshi Takao, Shinji Sakamoto, Yuko Okahisa, Keitaro Matsuo, Manabu Takaki, Yoshiki Kishi, Norihito Yamada. Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: an exploratory analysis. Drug and Alcohol Dependence, 2022, 109365, ISSN 0376-8716.

doi: 10.1016/j.drugalcdep.2022.109365
Otsuka
71
7387Neeraj NarulaHamilton Health SciencesComparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s DiseaseNarula, Neeraj; Wong, Emily C.L.; Dulai, Parambir S.; Marshall, John K.; Jairath, Vipul; Reinisch, Walter. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease. The American Journal of Gastroenterology: April 15, 2022 - Volume - Issue - 10.14309/ajg.0000000000001795.

doi: 10.14309/ajg.0000000000001795
AbbVie, Johnson & Johnson, Takeda449
7388Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patientsGhang B, Kim J, Yoo. BPOS0284 CHANGES OF ESTIMATED GLOMERULAR FILTRATION RATE AFTER LONG-TERM FEBUXOSTAT OR ALLOPURINOL TREATMENT IN GOUT PATIENTS. Annals of the Rheumatic Diseases 2022;81:386 .

https://ard.bmj.com/content/81/Suppl_1/386.1.full
Takeda1N/A
7388Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patientsByeongzu Ghang, Jinseok Kim. Effects of long-term febuxostat or allopurinol on the progression of chronic kidney disease. Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022 p271 O-54.

https://kcr2022.com/download/KCR2022_Abstract%20Book.pdf?ver=8
TakedaN/AN/A
7414Nobuyuki HoritaYokohama City University HospitalProgression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis.Horita, N. Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. Cancers 2023, 15, 185.

doi: 10.3390/cancers15010185
Roche00
7414Nobuyuki HoritaYokohama City University HospitalProgression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis.Ayaka Maeda, Kaoru Takase-Minegishi, Yohei Kirino, Naoki Hamada, Yosuke Kunishita, Ryusuke Yoshimi, Akira Meguro, Ho Namkoong, Nobuyuki Horita, Hideaki Nakajima, Yokohama City University irAE Working Group. Immune checkpoint inhibitor–induced arthralgia is tightly associated with improved overall survival in cancer patients. Rheumatology, 2022;. keac519.

doi : 10.1093/rheumatology/keac519
Roche12
7591, 7392Neeraj NarulaHamilton Health SciencesPredictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s DiseaseWong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug 24:S1542-3565(22)00811-4.

doi : 10.1016/j.cgh.2022.08.015
AbbVie, Johnson & Johnson, Pfizer, Takeda50
7591, 7392Neeraj NarulaHamilton Health SciencesPredictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s DiseaseEmily C L Wong, BHSc, Parambir S Dulai, MD, John K Marshall, MD, MSc, FRCPC, Vipul Jairath, MD, PhD, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH, FRCPC. Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease. Inflammatory Bowel Diseases. 2022. izac231.

doi : 10.1093/ibd/izac231
AbbVie, Takeda, Pfizer10
7609Joao Pedro FerreiraPorto UniversityThe impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baselineFerreira JP, Sharma A, Vasques-Nóvoa F, Angélico-Gonçalves A, Leite AR, Borges-Canha M, Carvalho D, Packer M, Zannad F, Leite-Moreira A, Neves JS. Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes. Eur J Heart Fail. 2022 Aug 23.

doi: 10.1002/ejhf.2660
GlaxoSmithKline33

2021

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetric ScorePubMed Citation Total
3288Marc-Antoine SparfelTours HospitalMIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trialsLaw-Wan J, Sparfel M, Derolez S, et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open 2021;7:e001882.

doi: 10.1136/rmdopen-2021-001882
AbbVie, Pfizer, UCB46
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaFrew, J. W., Singh, N., Jiang, C. S., Vaughan, R., & Krueger, J. G. (2021). The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa. Frontiers in Medicine.

doi: 10.3389/fmed.2021.603281
AbbVie
22
3762Lin WangJohns Hopkins School of Public Health, Johns Hopkins Hospital The relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
Lin Wang, MD, PhD, Channing Paller, MD, Hwanhee Hong, PhD, Lori Rosman, MLS, Anthony De Felice, MHS, Otis Brawley, MD, G Caleb Alexander, MD, MS, Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis, JNCI: Journal of the National Cancer Institute, 2021;, djab071,

doi: 10.1093/jnci/djab071
Pfizer, Project Data Sphere
205
4036Akira KimataUniversity of TsukubaOptimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trialsAkira Kimata, Akihiko Nogami, Hiro Yamasaki, Tomohiro Ohigashi, Masahiko Gosho, Miyako Igarashi, Yukio Sekiguchi, Masaki Ieda, Hugh Calkins, Kazutaka Aonuma, Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials, Journal of Cardiology, 2021, ISSN 0914-5087,

doi: 10.1016/j.jjcc.2020.12.010
Boehringer Ingelheim
22
4043Janneke van der WoudeErasmus Medical CenterEffect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysisJ A M Sleutjes, J E Roeters van Lennep, E Boersma, A C de Vries, C J van der Woude, P292 Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysis, Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S322–S323.

doi: 10.1093/ecco-jcc/jjab076.416
Pfizer
1N/A
4043Janneke van der WoudeErasmus Medical CenterEffect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysisSleutjes, JAM, Roeters van Lennep, JE, Boersma, E, et al. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther. 2021; 00: 1– 14.

doi: 10.1111/apt.16580
Pfizer
64
4316Martin OkunFort HealthcareGeospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis.268 Analysis of association between variation in ambient solar ultraviolet exposure and disease severity for patients with moderate-severe psoriasis
Okun, T.S. et al.
Journal of Investigative Dermatology, Volume 141, Issue 5, S48

doi: 10.1016/j.jid.2021.02.290
AbbVie
0N/A
4330Laure GossecSorbonne UniversitéDomains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i)Duarte C, Santos EJF, Ferreira RJO, et al. Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients RMD Open 2021;7:e001539.

doi: 10.1136/rmdopen-2020-001539
Pfizer
56
4918Nina HilkensRadboudumc NijmegenAssociation between blood pressure, blood pressure variability and the risk of post-stroke dementiaHilkens, Nina A.; Klijn, Catharina J.M.; Richard, Edo Blood pressure, blood pressure variability and the risk of poststroke dementia, Journal of Hypertension: March 11, 2021 - Volume Publish Ahead of Print - Issue

doi: 10.1097/HJH.0000000000002841
Boehringer Ingelheim
02
5073Philip RobinsonUniversity of QueenslandAssessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial dataTam, H.K.J., Nash, P. and Robinson, P.C. (2021), The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. ACR Open Rheumatology.

doi: 10.1002/acr2.11312
Pfizer
51
5074Sebastian ZundlerUniversity Hospital ErlangenEvaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysisBecker E, Dedden M, Gall C, et al. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut Published Online First: 30 August 2021.

doi: 10.1136/gutjnl-2021-324868
Takeda
5213
5086Junko TakeshitaUniversity of Pennsylvania A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases560 Racial/ethnic diversity in U.S. clinical trials for acne, atopic dermatitis, and psoriasis
Sevagamoorthy, A. et al.
Journal of Investigative Dermatology, Volume 141, Issue 5, S97

doi: 10.1016/j.jid.2021.02.587
AbbVie, Lilly, Regeneron
0N/A
5095Mathilde NijkeuterUniversity Medical Center UtrechtAssessing bleeding risk in patients with cancer-associated thrombosis de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, C Ruiz Artacho P, Vanassche T, Nijkeuter M. Estimating Bleeding Risk in Patients with Cancer-associated Thrombosis: External Validation of Existing Risk Scores and Development of a New Risk Score [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1).

https://abstracts.isth.org/abstract/estimating-bleeding-risk-in-patients-with-cancer-associated-thrombosis-external-validation-of-existing-risk-scores-and-development-of-a-new-risk-score/. Accessed July 23, 2021.
Daiichi Sankyo
511
5095Mathilde NijkeuterUniversity Medical Center UtrechtAssessing bleeding risk in patients with cancer-associated thrombosisde Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, Ruiz Artacho PC, Vanassche T, Nijkeuter M. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. Thromb Haemost. 2021 Sep 20.

doi: 10.1055/s-0041-1735251
Daiichi Sankyo511
5096Joo Sang LeeSamsung Medical Center, South KoreaHarnessing genetic interactions to advance precision cancer medicineSynthetic lethality-mediated precision oncology via the tumor transcriptome. Lee, Joo Sang et al.
Cell, Volume 184, Issue 9, 2487 - 2502.e13.

doi: 10.1016/j.cell.2021.03.030
Tempus Labs
13036
5098Christopher BaethgeUniversity of Cologne Medical SchoolDose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysisRink L, Adams A, Braun C, Bschor T, Kuhr K, Baethge C. Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom 2021.

doi: 10.1159/000520554
Lilly64
5163Susan BatesColumbia University Medical CenterAssessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial dataKeith Sigel, Mengxi Zhou, Yeun-Hee Anna Park, Tinaye Mutetwa, Girish Nadkarni, Celine Yeh, Paz Polak, Carlie Sigel, Thierry Conroy, Béata Juzyna, Mark Ychou, Tito Fojo, Juan P Wisnivesky, Susan E. Bates, Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans, Seminars in Oncology, 2021, ISSN 0093-7754.

doi: 10.1053/j.seminoncol.2021.02.001
Celgene Corporation
17
5165Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostatGhang B, Lee JS, Kim J, Yoo B. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: Another story of the CARES trial. J Rheum Dis 2021; 28(1):219.

Abstract
Takeda
N/AN/A
5166Thomas MetkusJohns Hopkins University School of MedicineSevere sepsis in the cardiac intensive care unit: management strategies and outcomesDugan, Eunice; Stephens, R. Scott; Schulman, Steven; Metkus, Thomas 1205: Sepsis in the Cardiac Intensive Care Unit: Demographics and Outcomes, Critical Care Medicine: January 2021 - Volume 49 - Issue 1 - p 605

doi: 10.1097/01.ccm.0000730708.28818.5e
Lilly
0N/A
5166Thomas MetkusJohns Hopkins University School of MedicineSevere sepsis in the cardiac intensive care unit: management strategies and outcomesFeldman, E. W., Dugan, E., Stephens, R. S., Schulman, S., Zakaria, S., & Metkus, T. (2021). Presentation and outcomes of sepsis in the cardiac intensive care unit. American Heart Journal Plus: Cardiology Research and Practice, 7, 100040.

doi: 10.1016/j.ahjo.2021.100040
Lilly
11
5207Fasihul KhanUniversity of NottinghamA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosisKhan FA, Stewart I, Saini G, Robinson KA, Jenkins RG. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix-metalloproteinase-7 in IPF. Eur Respir J. 2021 Sep 29:2101612. PMID: 34588192.

doi: 10.1183/13993003.01612-2021
BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche
911
5207Fasihul KhanUniversity of NottinghamA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosisA systematic review and individual participant data meta-analysis of MMP-7 and outcomes in idiopathic pulmonary fibrosis. Fasihul Khan, Iain Stewart, Gauri Saini, Karen A Robinson, Gisli Jenkins. European Respiratory Journal Sep 2021, 58 (suppl 65) PA395;

doi: 10.1183/13993003.congress-2021.PA395
BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche
311
5292Désirée van der HeijdeLeiden University Medical CenterMeasurement properties of the instruments used in the outcome assessment of axial spondyloarthritisBoel A, Navarro-Compán V, van der Heijde D. Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis. RMD Open 2021;7:e001839.

doi: 10.1136/rmdopen-2021-001839
UCB
60
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning ApproachDuong S, Crowson C, Atkinson E, Athreya A, Davis J, Matteson E, Weinshilboum R, Wang L, Myasoedova E. Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10).

https://acrabstracts.org/abstract/clinical-predictors-of-response-to-methotrexate-in-patients-with-rheumatoid-arthritis-a-machine-learning-approach-using-clinical-trial-data/
Roche, UCB
16
5456Terina MartinezCritical Path InstituteValidation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular DystrophyModeling informative drop out in a disease progression model of Duchenne Muscular Dystrophy. Rhoda Muse, Jane Larkindale, Sarah Kim, Stephan Schmidt, Juan Francisco Morales, Sudhir Sivakumaran, Ramona Belfiore-Oshan, Varun Aggarwal, Klaus Romero, Jackson Burton and Diane Corey. Statistics and PMx e.g. MBMA, Bayesian application/method, trial design, optimal design, machine learning, data mining. ACoP12 (2021) STPM-198

www.go-acop.org/?abstract=198
CureDuchenneN/AN/A
5456Terina MartinezCritical Path InstituteValidation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular DystrophyRamona Belfiore-Oshan, Varun Aggarwal, Rhoda Muse, Sarah Kim, Stephan Schmidt, Juan Francisco Morales, Karthik Linganeni, Sudhir Sivakumaran, Diane Corey, Klaus Romero, Terina Martinez. Acceleration of clinical trial design in Duchenne Muscular Dystrophy building a model-based Clinical Trial Simulation Tool. The Muscular Dystrophy Association (MDA) Clinical & Scientific conference, March 13-16, 2022 (Abstract).

https://mdaconference.org/node/1556
CureDuchenneN/AN/A
5567Neeraj NarulaHamilton Health Sciences Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn’s Disease: An EXTEND Post-Hoc AnalysisNarula N, Wong ECL, Colombel J, et alPredicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) Gut Published Online First: 25 March 2021.

doi: 10.1136/gutjnl-2020-323799
AbbVie
98
5567Neeraj NarulaHamilton Health Sciences Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn’s Disease: An EXTEND Post-Hoc AnalysisSa467 THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD) PERFORMS BETTER THAN THE SES-CD FOR PREDICTION OF ENDOSCOPIC REMISSION IN CROHN'S DISEASE. Narula, Neeraj et al.
Gastroenterology, Volume 160, Issue 6, S-509.

doi: 10.1016/S0016-5085(21)01923-5
AbbVie
1N/A
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersHopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers. 2021; 13(5):1176.

doi: 10.3390/cancers13051176
Roche412
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersAbuhelwa AY, Kichenadasse G, McKinnon RA, Rowland A, Hopkins AM, Sorich MJ. Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer. Cancers. 2021; 13(9):2001.

doi: 10.3390/cancers13092001
Roche38
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersHopkins, A.M., Kichenadasse, G., McKinnon, R.A. et al. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer (2021).

doi: 10.1038/s41416-021-01606-4
Roche11726
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersHopkins, A. M., Abuhelwa, A. Y., McKinnon, R. A., Logan, J. M., Kichenadasse, G., Rowland, A., & Sorich, M. J. (2021). Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials. European Journal of Cancer.

doi: 10.1016/j.ejca.2021.10.020
Roche21
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersAhmad Y Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A McKinnon, Andrew Rowland, Michael J Sorich, Ashley M Hopkins. Enhanced Bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy. Clinical Genitourinary Cancer, 2021.

doi: 10.1016/j.clgc.2021.11.010
Roche36
5925Min Hwan KimYonsei University College of MedicineAnalysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical responseOn-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.

Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jeeye Kim, Hyung Seok Park, Seho Park, Youngup Cho, Byeong-Woo Park, Seung Il Kim, Joon Jeong, and Joohyuk Sohn. Journal of Clinical Oncology 2021 39:15_suppl, 1066-1066.

doi: 10.1200/JCO.2021.39.15_suppl.1066
Pfizer1N/A
5931Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trialKayali, M., Abi Jaoude, J., Mohammed, M. et al. Post-mastectomy Radiation Therapy in Triple-Negative Breast Cancer Patients: Analysis of the BEATRICE Trial. Ann Surg Oncol 29, 460–466 (2022).

doi: 10.1245/s10434-021-10511-2
Roche45
5933, 5208Ahmad AbuhelwaUniversity of South Australia Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritisAbuhelwa AY, Foster DJR, Manning-Bennett A, et al. Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. Therapeutic Advances in Musculoskeletal Disease. January 2021.

doi: 10.1177/1759720X211009020
Roche50
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Zhou J, Wong AH, Wang H, et al. 329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials. Journal for ImmunoTherapy of Cancer 2021;9:

doi: 10.1136/jitc-2021-SITC2021.329
Roche
1N/A
5945Neeraj NarulaHamilton Health SciencesPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITYNarula, N., Wong, E., Colombel, J. F., Riddell, R., Marshall, J., Reinisch, W., & Dulai, P. (2021). DOP03 Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in Ulcerative Colitis. Journal of Crohn’s and Colitis, 15(Supplement_1), S042–S043.

doi: 10.1093/ecco-jcc/jjab073.042
Takeda
010
5945Neeraj NarulaHamilton Health SciencesPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITYNarula, N., Wong, E. C., Colombel, J. F., Riddell, R., Marshall, J. K., Reinisch, W., & Dulai, P. S. (2021). Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. Published.

doi: 10.1016/j.cgh.2021.07.005
Takeda110
5951Mathilde NijkeuterUniversity Medical Center UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolismde Winter MA, Dorresteijn JAN, Carrier M, Cohen AT, Hansen J-, Kaasjager HAH, Middeldorp S, Raskob GE,Sørensen HT, Visseren FLJ, Wells PS, Büller HR, Nijkeuter M. Individual Benefits and Harms of Extended Anticoagulation in Patients with Venous Thromboembolism: The VTE-PREDICT Model [abstract]. Res PractThromb Haemost. 2021; 5 (Suppl 1).

https://abstracts.isth.org/abstract/individual-benefi ts-and-harms-of-extended-anticoagulation-in-patients-with-venous-thromboembolism-the-vte-predict-model/. Accessed July 23, 2021.
Boehringer Ingelheim, Daiichi Sankyo
N/AN/A
5984David BakerQueen Mary University of LondonExploring possibilities to improve the risk benefit balance through analysis of the ocrelizumab phase II extension studyDavid Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson. Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2021; uxab015.

doi: 10.1093/cei/uxab015
Roche
2314
6062Alexander MeiselUniversity Hospital of ZurichNeutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-CombinationsMeisel, A., Mark, M., Haider, A., Holer, L., Hayoz, S., Gebhard, C., Bengs, S., Hochmair, M., Cappuzzo, F., Reck, M., von Moos, R., & Stenner-Liewen, F. (2021). 1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT). Annals of Oncology, 32, S996.

doi: 10.1016/j.annonc.2021.08.1881.
Roche
0N/A
6064Neeraj NarulaHamilton Health SciencesComparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative ColitisNarula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 Jul 28:S1542-3565(21)00820-X. PMID: 34329776.

doi: 10.1016/j.cgh.2021.07.038
Johnson & Johnson, Takeda326
6489Line UhrenholtAalborg University HospitalTapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthritis: a systematic review of randomised controlled trialsLine Uhrenholt, Robin Christensen, Wilfred K H Dinesen, Caroline H Liboriussen, Stine S Andersen, Lene Dreyer, Annette Schlemmer, Ellen-Margrethe Hauge, Conni Skrubbeltrang, Peter C Taylor, Salome Kristensen. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology, 2021.

doi: 10.1093/rheumatology/keab902
AbbVie
134
6499, 5323, 5289Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancerPrediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. Modi, Natansh D. et al. The Breast, Volume 58, 57 – 62.

doi: 10.1016/j.breast.2021.04.003
Lilly113
6642Neeraj NarulaHamilton Health SciencesModified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s DiseaseNeeraj Narula, Emily C L Wong, Jean-Frederic Colombel, William J Sandborn, Marc Ferrante, John K Marshall, Walter Reinisch, Parambir S Dulai, Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease, Journal of Crohn's and Colitis, Volume 16, Issue 4, April 2022, Pages 616–624.

Doi:10.1093/ecco-jcc/jjab183
AbbVie, Johnson & Johnson, Takeda11
6686Neeraj NarulaHamilton Health SciencesExtended Validation of an Ulcerative Colitis Vedolizumab Decision Support ToolParambir S Dulai, MD, Emily C L Wong, BS, Walter Reinisch, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Neeraj Narula, MD, Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases, 2021; izab310,

doi: 10.1093/ibd/izab310
Takeda
43

2020

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetric ScorePubMed Citation Total
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaFrew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Dermal Tunnels Influence Time to Clinical Response and Family History Influences Time to Loss of Clinical Response in Hidradenitis Suppurativa Patients Treated with Adalimumab.
Clinical and Experimental Dermatology. Accepted Author Manuscript.

doi: 10.1111/ced.14448
AbbVie
07
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaFrew J, Jiang C, Singh N, Navrazhina K, Vaughan R, Krueger J, Quantifying the Natural Variation in Lesion Counts Over Time in Untreated Hidradenitis Suppurativa: Implications
for Outcome Measures and Trial Design, JAAD International (2020),

doi: 10.1016/j.jdin.2020.09.005

AbbVie
22
3369Michael WardNational Institutes of Health (NIH)Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing SpondylitisWang R, Dasgupta A, Ward M. Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

https://acrabstracts.org/abstract/predicting-major-treatment-response-to-tumor-necrosis-factor-inhibitorsin-patients-with-ankylosing-spondylitis/.
AbbVie, Pfizer
N/AN/A
4116Sharon StrausSt. Michael's HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisVeroniki AA, Ashoor H, Rios P, Seitidis G, Mavridis D, Holroyd-Leduc J, Straus S, Tricco A. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: An individual patient data network meta-analysis. In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020;(9 Suppl 1):455.

doi: 10.1002/14651858.CD202001
AbbVie
5143
4117John FrewRockefeller UniversityPredictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa Malignancy and Infection Risk During Adalimumab Therapy in Hidradenitis Suppurativa. Frew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Clin Exp Dermatol. Accepted Author Manuscript.

doi: 10.1111/ced.14264

AbbVie
04
4319Maria Alice FranzoiJules Bordet Institut Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials. Franzoi, M.A. et al. Annals of Oncology, Volume 31, S71.

doi: 10.1016/j.annonc.2020.03.253
Lilly
0N/A
4319Maria Alice FranzoiJules Bordet Institut Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapyMaria Alice Franzoi, MD, Daniel Eiger, MD, Lieveke Ameye, MSc, Noam Ponde, MD, Rafael Caparica, MD, Claudia De Angelis, MD, Mariana Brandão, MD, Christine Desmedt, PhD, Serena Di Cosimo, MD, Nuria Kotecki, MD, Matteo Lambertini, MD PhD, Ahmad Awada, MD PhD, Martine Piccart, MD PhD, Evandro de Azambuja, MD PhD, Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy, JNCI: Journal of the National Cancer Institute, djaa116,

doi: 10.1093/jnci/djaa116
Lilly
1512
4327Michael SzarekSUNY Downstate Medical CenterAnalysis of Total Events and Hospitalizations in the SPARCL StudySzarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16.

doi: 10.1016/j.jacc.2020.03.015
Pfizer
707
4540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trialWilkinson, C., Wu, J., Searle, S.D. et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 18, 401 (2020).

doi: 10.1186/s12916-020-01870-w
Daiichi Sankyo
3025
5327Jose Antonio Pereira da SilvaUniversidade de Coimbra, PortugalLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis individual patient data meta-analysisFerreira RJO, Welsing PMJ, Jacobs JWG, et al. Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Annals of the Rheumatic Diseases Published Online First: 06 October 2020.

doi: 10.1136/annrheumdis-2020-217171
AbbVie, Pfizer, Roche, UCB
619
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersConcomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland and Michael J. Sorich.
Clin Cancer Res October 15 2020 (26) (20) 5487-5493;

doi: 10.1158/1078-0432.CCR-20-1876
Roche11133
5930Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy Boost in Women with HER-2 positive Breast CancerAbi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart M, Poortmans P, Zeidan YH. De-intensifying radiation therapy in HER-2 positive breast cancer: to boost or not to boost?. International Journal of Radiation Oncology-Biology-Physics. 2020 Nov 15;108(4):1040-6.

doi : 10.1016/j.ijrobp.2020.06.078
Roche233
5933, 5208Ahmad AbuhelwaUniversity of South Australia Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritisAbuhelwa, A.Y., Hopkins, A.M., Sorich, M.J. et al. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep 10, 18634 (2020).

doi: 10.1038/s41598-020-75673-7
Roche
18

2019

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetric ScorePubMed Citation Total
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaClinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data
Frew, John W. et al.
Journal of the American Academy of Dermatology, Volume 0, Issue 0

doi: 10.1016/j.jaad.2019.12.044
AbbVie
214
4036Akira KimataUniversity of TsukubaOptimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trialsCirculation. Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019, Volume: 140, Issue: 25, Pages: e965-e1011, DOI: (10.1161/CIR.0000000000000742)

doi: 10.1161/CIR.0000000000000742
Boehringer Ingelheim
349